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Stem cell technology has gained considerable recognition since its inception to advance 
disease modeling and drug screening. This is especially true for tissues that are difficult to study 
due to tissue sensitivity and limited regenerative capacity, such as the heart. Previous work in stem 
cell-derived cardiac tissue has exploited how we can engineer biologically functional heart tissue 
by providing the appropriate external stimuli to facilitate tissue development. The goal of this 
dissertation is to explore the potentials of stem cell cardiac organoid models to recapitulate heart 
development and implement analytical computational tools to study cardiac physiology. These 
new tools were implemented as potential advancements in drug screening applications for better 
predictions of drug-related cardiotoxicity.  
 Cardiac organoids, generated via micropatterning techniques, were explored to determine 
how controlling engineering parameters, specifically the geometry, direct tissue fate and organoid 
function. The advantage of cardiac organoid models is the ability to recapitulate and study human 
tissue morphogenesis and development, which has currently been restricted through animal 
models.  The cardiac organoids demonstrated responsiveness manifested as impairments to tissue 
formation and contractile functions as a result of developmental drug toxicity. Single-cell genomic 
characterization of cardiac organoids unveiled a co-emergence of cardiac and endoderm tissue, 
which is seen in vivo through paracrine signaling between the liver and heart. We then 
implemented computational tools based on nonlinear mathematical analysis to evaluate the cardiac 
physiological drug response of stem cell-derived cardiomyocytes. This dissertation discusses in 
vitro tissue platforms as well as computational tools to study drug-induced cardiotoxicity. Using 
these tools, we can extend current toolboxes of understanding cardiac physiology for advanced 
investigations of stem-cell based cardiac tissue engineering.  
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List of Figures 
Figure 1. Stem cell biology and human development. Potentials of using in vitro induced 
pluripotent stem cell biology to model in vivo human cell and tissue development. 
Figure 2. Stem cell organoids exhibiting spatial-organization and features that resemble 
native in vivo organs. Stem cell organoids with spatial organization and patterning have been 
engineered to model numerous organs including (a) brain39, (b) kidney59, (c) intestinal42, and (d) 
retinal43. All figures reproduced with copyright permissions. 
Figure 3. Stem cell organoids engineered through precise microenvironment control. (a) 
Intestinal organoids generated in synthetic PEG-4MAL hydrogels46; (b) microfluidic-controlled 
epiblast and amnion structures60; (c) micropatterning of human stem cells to model germ layer 
formation49. All figures reproduced with copyright permissions.  
Figure 4. Cardiac organoids derived from cardiomyocytes differentiated from human 
induced pluripotent stem cells. Various cardiac organoid models have been developed by 
researchers. (a) Vascularized cardiac organoid17; (b) self-organized cardiac organoid 
microchamber54. All figures reproduced with copyright permissions.  
Figure 5. Schematic of procedure and process of PDMS stencil fabrication 
(a) Schematic outlining key steps of the entire procedure. (b) SU8 master with a small amount of 
PDMS prepolymer. (c) Completed assembly of the patterned SU8 master-PDMS-transparency-
glass slide construct. (d) Thin film of PDMS removed from the assembly after curing and then 
placed on top of the (e) optically clear PEG grafted surface55. Figure reproduced from Hoang et 
al. 2018 Nature Protocols. 




Figure 6. Quality control of patterned hiPSC pluripotency. The micropatterned hiPSC colonies 
maintained the expression of pluripotency markers of (from left to right) OCT4, NANOG, E-
cadherin, SOX2, and SSEA4. Scale bar, 200 µm. 
Figure 7. Confluent micropatterned hiPSC colonies. Bright-field microscopy images of arrays 
of micropatterned hiPSCs with different sizes and shapes. Scale bar, 400 µm. Clockwise: 200 µm 
circles, 400 µm circles, triangles, and 600 µm circles. 
Figure 8. Cardiac differentiation timeline to generate cardiac organoids. Patterned cell 
morphology changes from 2D monolayer of cells (D0) into 3D tissue (D6 onward) throughout 
differentiation; scale bars 600 µm. 
Figure 9. Cardiac organoid function and structure characterization. (a) Motion tracking 
analysis based on vector computation of pixel movement generates contraction velocity 
waveforms representing beat cycles of the cardiac organoids. (b) Immunofluorescence staining 
used to compute the Area Ratio, which is the area of cardiac tissue (cTnT) coverage relative to the 
area of the entire pattern. (c) Confocal imaging was used to capture z-stacks of the tissues, which 
were reconstructed for 3D morphological scoring of the height and full-width at half-maximum 
(FWHM). Scale bars 200 µm. 
Figure 10. Differentiation from pluripotency into cardiac organoids. (a) 24h after CHIR 
treatment, patterned hiPSCs express mesodermal marker brachyury. (d) On Day 8 of 
differentiation, cardiac organoids express ISL1, followed by (d) NKX2.5 and GATA4 on Day 10, 
indicative of early cardiac progenitor cells; scale bars 200 µm. (b – top row) The spatial-organized 
cardiac organoids showed cardiac muscle on the top center with cardiomyocyte-specific proteins 
(cardiac troponin T (cTnT), β myosin heavy chain (MHC-β) sarcomeric α-actinin and cardiac 
troponin I (cTnI)) and smooth muscle-like cells on the perimeter of the organoids with stromal cell 




markers (smooth muscle actin (α-SMA), calponin, transgelin (α-SM22) and vimentin). Scale bar, 
200 µm. (b – bottom row) confocal microscopy images of cardiomyocytes on the cardiac 
organoids. Scale bar, 50 µm.  
Figure 11. Geometry effect on cardiac organoid function and structure. (a) Confocal 
reconstructions of cardiac organoids generated in circular, triangular, and square shapes; scale bars 
200 µm. From comparison of contraction function of cardiac organoids as influenced by shape 
geometry, (b) triangular and square organoids exhibited significantly decreased contraction 
velocity (n ≥ 10, *p = 0.0024), but (c) significantly faster beat rate (n ≥ 9, *p ≤ 0.0001) with (d) 
longer beat duration (n ≥ 9, *p ≤ 0.0001) relative to circular organoids. Structural 3D 
morphological scoring of cardiac organoids showed that circle shapes produced organoids that 
were significantly larger in area ratio (n ≥ 16, *p ≤ 0.0001) than triangle and square organoids. 
Only triangle organoids produced significantly decreased tissue height (n ≥ 9, *p = 0.0013) and 
both triangular and square organoids had significantly smaller FWHM (n ≥ 9, *p ≤ 0.0001). (h) 
Structure-function correlation plot illustrating the effect of structure on cardiac contraction. (i) 
Structure-structure correlation plot illustrating shape influence on 3D architecture. In all panels, 
box plots show the minimum, maximum, median, and 25th and 75th percentiles, and statistical 
analysis was performed based on analysis of variance (ANOVA) with Tukey’s multiple 
comparison test. 
Figure 12. Pattern size effects on cardiac organoid characteristics. (a) Cardiac organoids 
generated from the circular patterns with different sizes (200 µm – 1000 µm in diameter) showed 
spatial-organization of cardiomyocytes and stromal cells and 3D dome-shape in the X-Z plane. 
Scale bar, 200 µm. Contractile motion analysis showed no significant differences in contraction 
velocity amongst the cardiac organoids generated from different pattern sizes, but 200-µm patterns 




generated the organoids with significant differences in beat rate and beat duration comparing to 
the other pattern sizes (n = 10, *p < 0.0001 for beat rate; *p < 0.0001 for beat duration). The area 
ratio between cardiomyocyte staining and entire pattern size showed significant larger coverage 
but higher variation in cardiac muscle differentiation on the cardiac organoids generated from the 
patterns with 200 µm, 800 µm and 1000 µm diameter (n = 9, *p ≤ 0.0001 between 200 µm and 
400/600 µm; *p ≤ 0.0001 between 400/600 and 800/1000 µm). The cardiac organoids generated 
from 600-µm diameter circles exhibited better 3D morphology with largest values in (f) height (n 
= 8, *p = 0.0126 between 200 µm and 600 µm; *p = 0.0126 between 600 and 800/1000 µm) and 
(g) FWHM (n = 8, *p ≤ 0.0001 between 600 µm and 200/400 µm; *p ≤ 0.0001 between 600 and 
800/1000 µm). (h) Structure-function correlation plot for the cardiac organoid generated from 
different pattern sizes showed close clustering of the circular patterns of 400 – 1000 µm diameters, 
except for 200 µm diameter. (i) Structure-structure correlation plot showed that 600-µm diameter 
circular pattern consistently produced the cardiac organoids with the largest 3D structure. (j) Gene 
expression analysis showed that larger pattern sizes (600 µm and 1000 µm diameter circles) were 
associated with high expression of cardiac muscle-related genes, while small pattern (200 µm 
diameter circle) was associated with high expression of stromal-related genes. In all panels, box 
plots show the minimum, maximum, median, and 25th and 75th percentiles, and statistical analysis 
was performed based on analysis of variance (ANOVA) with Tukey’s multiple comparison test. 
Figure 13. Gene expression patterns directed by pattern size. (a) Gene expression heatmap of 
104 genes assayed the cardiac organoids generated from 200 µm, 600 µm, and 1000 µm – diameter 
circular patterns. (b) Gene expression of cardiac-specific and smooth muscle/stromal genes 
normalized to the expression of GAPDH housekeeping gene. (c) The signaling-related genes 
showed highly differentiated expression. 




Figure 14. Cardiac organoid developmental toxicity to doxylamine succinate and 
thalidomide. (a) The timeline of cardiac organoid generation and continuous drug exposure. Epi-
fluorescent microscopy images of the cardiac organoids for comparison between untreated controls 
with (b) doxylamine succinate (category A drug) and (c) thalidomide (category X drug). The area 
ratio of cardiac muscle coverage showed (d) an increase with doxylamine succinate (n = 29, *p ≤ 
0.0001), but a decrease with thalidomide at high concentrations (n ≥ 28, *p ≤ 0.0001). The 
contraction velocity of cardiac contractile motion showed no drug effect from (f) either 
doxylamine succinate (g) or thalidomide. The beat rate showed (h) a decrease with doxylamine 
succinate (n ≥ 9, *p ≤ 0.0001), and an increase with thalidomide at 1 µM and 10 µM concentrations 
(n ≥ 12, *p ≤ 0.0001). (j) The cardiac organoids under doxylamine succinate exposure showed no 
drug effects on the 3D organoid morphology at all the tested concentrations. (k) Thalidomide 
exposure induced significant structural impairment on 3D organoid formation, showed as lower 
height (n ≥ 9, *p ≤ 0.0001) and FWHM (n ≥ 14, *p ≤ 0.0001) at high concentrations. Representative 
confocal microscopy images of the cardiac organoids of (k) untreated control and (m) 100 µM 
thalidomide exposure showed severe abnormal organoid formation for quantitative morphological 
scoring. 
Figure 15. Developmental toxicity assay of cardiac organoids in response to treatment with 
Amoxicillin (Category B). Amoxicillin showed moderate toxicity with decreased beat rate (two-
way student t-test, n ≥ 11, *p = 0.0048) and increased beat duration (two-way student t-test, n ≥ 
11, *p = 0.0013) at high concentrations. Amoxicillin treatment at low concentrations, however, 
produced smaller cardiac tissues in area ratio (two-way student t-test, n ≥ 18, *p = 0.0083 between 
Controls and 1 µM) and in height (two-way student t-test, n ≥ 7, *p ≤ 0.0001). 




Figure 16. Developmental toxicity assay of cardiac organoids in response to treatment with 
Rifampicin (Category C). In all assays, cardiac organoids failed to differentiate at 100 µM 
treatment, and toxicity was also observed in contraction velocity (two-way student t-test, n ≥ 12, 
*p = 0.0174), beat rate (two-way student t-test, n ≥ 12, *p = 0.0232), area ratio (two-way student 
t-test, n = 29, *p = 0.0123), height (two-way student t-test, n ≥ 10, *p ≤ 0.002 relative to controls) 
and in FWHM (two-way student t-test, n ≥ 21, *p = 0.0001). 
Figure 17. Developmental toxicity assay of cardiac organoids in response to treatment with 
Doxycycline (Category D). In all assays, cardiac organoids failed to differentiate at 100 µM 
treatment, and toxicity was also observed in contraction velocity (two-way student t-test, n ≥ 7, *p 
= 0.0036), beat rate (two-way student t-test, n ≥ 7, *p ≤ 0.0067), beat duration (two-way student t-
test, n ≥ 7, *p ≤ 0.0001),  and height (two-way student t-test, n = 8, *p ≤ 0.0061 relative to controls) 
and in FWHM (two-way student t-test, n ≥ 21, *p = 0.0001). 
Figure 18. Developmental toxicity assay of cardiac organoids in response to treatment with 
Lithium carbonate (Category D). No significant toxicity effects were seen in any contraction 
function. However, moderate toxicity was seen in all concentrations for the area ratio (ANOVA, 
n ≥ 26, *p ≤ 0.0001) and in FWHM (ANOVA, n ≥ 20, *p ≤ 0.0001) relative to the controls. 
Figure 19. Developmental toxicity assay of cardiac organoids in response to treatment with 
Phenytoin (Category D). Phenytoin showed no contractile functions at 100 µM concentration, 
with moderate effects at 1 µM on beat rate (two-way student t-test, n ≥ 11, *p = 0.0165) and beat 
duration (two-way student t-test, n ≥ 11, *p = 0.0101). Organoids were also smaller in area ratio 
at 10 µM treatment (two-way student t-test, n = 28, *p = 0.0006) and smaller at all concentrations 
in height (ANOVA, n ≥ 12, *p ≤ 0.0001) and FWHM (ANOVA, n=20, *p ≤ 0.0001) relative to 
controls. 




Figure 20. Developmental toxicity assay of cardiac organoids in response to treatment with 
Tretinoin (Category D). Cardiac tissue failed to develop at 10 µM concentrations with no 
contraction functions. Contraction velocity was lower at 0.1µM (two-way student t-test, n ≥ 7, *p 
= 0.0274), whereas beat rate was faster at 0.1µM and 1 µM (ANOVA, n ≥ 7, *p = 0.0001). Beat 
duration was significantly lower at 1 µM (two-way student t-test, n ≥ 7, *p ≤ 0.0001) as well. Low 
concentration of 0.1 µM also showed toxic effects on area ratio (two-way student t-test, n ≥ 12, *p 
≤ 0.0112), height (two-way student t-test, n ≥ 8, *p = 0.0004), and FWHM (two-way student t-
test, n ≥ 12, *p ≤ 0.0001). 
Figure 21. Developmental toxicity assay of cardiac organoids in response to treatment with 
Isotretinoin (Category X). Cardiac tissue failed to develop at 1 µM and 10 µM concentrations 
with no contraction functions. Low concentration of 1 µM resulted in faster beat rate (two-way 
student t-test, n ≥ 13, *p ≤ 0.0007) and smaller area ratio (two-way student t-test, n ≥ 31, *p ≤ 
0.0001). However, high concentrations produced organoids that were significantly taller in height 
(ANOVA, n ≥ 9, *p ≤ 0.0001) and larger in FWHM (ANOVA, n ≥ 12, *p ≤ 0.0001). 
Figure 22. Cardiac looping scored as a cardiac developmental toxicity evaluation in the 
zebrafish whole embryo culture assay (zWEC). Zebrafish embryo heart structures were scored 
based on loop structure, where (a) D-looped heart structures are the normal expected structure. No 
significant drug effect from (b) doxylamine succinate exposure, and a very mild toxicity level from 
high dosage exposure of (c) thalidomide. A sample size of n>40 embryos were analyzed for these 
treatment groups. 
Figure 23. Zebrafish whole embryo culture (zWEC) assay of cardiac looping for seven drug 
compounds. (a) Category B amoxicillin and (b) Category C rifampicin produced mild 
developmental toxic effect. (c-f) Category D drugs displayed developmental toxic effects ranging 




from moderate (lithum carbonate, phenytoin, and doxycycline) to severe (tretinoin). (g) Category 
X isotretnoin produced severe developmental toxic effects at all concentrations. (h) Morphological 
scoring was performed on heart structures of developing zebrafish embryos based on either normal 
(D-loop), reverse (L-loop), no loop, or no score where the heart did not express GFP and/or fall 
into the previous three categories. A sample size of n>19 embryos was used for all treatment 
groups. 
Figure 24. Single-cell RNA sequencing and bioinformatics workflow. (a) Single-cell RNA 
sequencing pipeline using 10X Genomics from sample preparation to data output using 
CellRanger. Single cell data is plotted as a series of violin plots for quality control. Quality control 
of output data involves filtering of (b) read counts, (c) detected features, and (d) percent 
mitochondrial counts. Single cell data is then clustered into cell types based on PCA 
dimensionality reduction and visualized using (e) t-SNE and (f) trajectory trees to identify cell 
types. 
Figure 25. Cell-specific gene identification of cardiomyocytes and stromal cells. (a) 
Cardiomyocytes were identified by locating the cell cluster expressing cardiomyocyte markers 
ACTN2, MYBPC3, and MYH6. (b) MYH6 expression showed to be highly specific to clusters 1 
and 7, identifying two sub-populations of cardiomyocytes. (c) Stromal cell markers TAGLN2 and 
ACTA2 confirmed the presence of stromal cells and (d) displayed scattered expression across 
multiple cell clusters, except in the cardiomyocyte populations. 
Figure 26. Heat map of top one hundred differentially expressed genes for cell cluster 
classification. Genes were filtered to only include the top 100 genes with the highest variance. 
These differentially expressed genes were used to approximate the classification of the cell type 
composing each cluster. 




Figure 27. Integrated t-SNE plot of classified cell clusters composing 200 µm, 600 µm, and 
1000 µm cardiac organoids. t-SNE plot of more than 63,000 cells colored by cell type. Cells were 
clustered based on PCA and graph-based clustering. 
Figure 28. Classification of cell clusters using trajectory analysis and identification of cell-
specific genes. (a) Trajectory analysis of cardiac organoids of different sizes fall in three primary 
cell lineage branches: cardiac, stromal, and endodermal. (b) Lineage specific markers were 
mapped to locate and further classify the cell populations illustrated within the t-SNE. 
Figure 29. The t-SNE expression maps for vasculogenic, cardiogenic, and hepatogenic 
signaling factors in the cardiac organoids. Cardiac organoids showed low indication of 
vasculogenesis, but high indication of paracrine signaling between mesodermal cardiac lineages 
and endodermal hepatic lineages 
Figure 30. Fractional composition of cell types in small, mid-size, and large organoids. 
Cardiac organoids of different sizes drives differential cell specification. Small organoids (200 
micron) had higher fractional compositions of early cell types and progenitor cells. Mid-size 
organoids (600 micron) had the highest fraction of cardiomyocytes and smooth muscle cells. Large 
organoids (1000 micron) had the highest fraction of endodermal cells. 
Figure 31. Heat map and pathway analysis of cardiac organoid cell types. Gene ontology 
pathway analysis was performed using a range of 10-20 genes for each major cell cluster. 
Figure 32. Cardiac, stromal, and endodermal gene expression patterns relative to cardiac 
organoid size. Fold change expression patterns were plotted to compare gene expression across 
the three pattern sizes. Genes were selected based on specificity to cardiac, endodermal, and 
stromal cell lineages. 




Figure 33. Process workflow of hiPSC-CM contractile motion characterization. The 
contractile motion of hiPSC-CMs was recorded as beating videos, which were analyzed using 
motion tracking software to generate motion vectors and contractile motion waveforms. This data 
was then analyzed using PSR to compute the dimensional parameters. The embedding dimension 
characterizes the regularity of the contractile motions, which reflects the changes in beat rhythm 
and overall gross motion. The fractal dimension characterizes the complexity, which reflects the 
secondary aberrations present within each beat cycle128.   
Figure 34. Reconstruction of cardiac motion waveforms into phase space. The phase spaces 
of a regular (a) and a complex (c) cardiac contractile motions are plotted along with their 
corresponding motion waveforms (b, d). The embedding dimensions from a single motion 
waveform were computed from PSR to compare the differences in regularity between two 
contractile motions (e). The regularity dimensions derived the embedding dimensions were plotted 
with respect to τ (f). The average fractal dimension across all τ was computed from PSR (g) and 
then plotted with respect to τ (h)128. 
Figure 35. PSR analysis of secondary system aberrations. A motion waveform was supplied 
with random noise ranging from 2.5%-50% (a), and corresponding phase space was reconstructed 
to compute the dimensional parameters respectively for different degrees of noise. No significant 
difference was found based on embedding and regularity dimensions among the contractile 
motions with different noise level (b, c), but fractal dimensions exhibited significant increase with 
the increase of the noise level (d, e)128.    
Figure 36. PSR analysis of propranolol treated hiPSC-CMs. The application of propranolol to 
hiPSC-CMs increased the average embedding dimension with the increase of drug concentrations, 




which correlated to a reduction in regularity dimension. No significant difference was found for 
fractal dimension between baseline control and drug exposure128. 
Figure 37. PSR analysis of E4031 treated hiPSC-CMs. E4031 induced significant increases in 
the embedding and regularity dimensions between controls and drug exposure. High dosage of 
E4031 (100 nM) induced a significant increase of fractal dimension on the hiPSC-CMs in 
comparison to the control and low dosage128. 
Figure 38. PSR analysis of metoprolol treated hiPSC-CMs. PSR analysis showed that treatment 
of hiPSC-CM with metoprolol has no significant influence on the embedding, regularity and fractal 
dimensions128. 
Figure 39. PSR analysis of isoproterenol treated hiPSC-CMs. Low dosage of isoproterenol (50 
nM) decreased the embedding dimension, which corresponded to a rise in the regularity of the 
system. In contrast, high dosage of isoproterenol (10 µM) increased the embedding and fractal 
dimensions, indicating the contractile motions of hiPSC-CMs gained aberrations but lost 
regularity128. 
Figure 40. Drug-induced arrhythmia comparison of motion tracking versus calcium flux. 
Brightfield and fluorescence videos of drug-treated GCaMP6f hiPSC-CMs were recorded for (a) 
motion tracking analysis and (b) calcium flux analysis. (c) Waveforms generated from each assay 
were subjected to PSR analysis. PSR analysis of both methods illustrated the sensitivities to drug 
interference by quantifying changes in the embedding and fractal dimensions as a result of (d) 
isoproterenol and (e) propranolol induced-arrhythmias. All scale bars are 100 μm128. 
Figure 41. Nonlinear reconstruction of time series contractile motion signals. (a) Contraction 
motion waveforms were analyzed using phase space reconstruction to determine the fractal 
properties of the signals, including two parameter capacity dimension and correlation dimension, 




which characterize the geometric space and distribution dynamics of the signals. (b) Two hiPSC-
CM clusters (Cluster A and Cluster B) exhibiting comparable contractile physiology, (c) which 
were compared in time domain and respective nonlinear phase spaces. (d) The capacity dimension 
with respect to time lag (τ) was comparable between the two clusters, (e) but the correlation 
dimension with respect to embedding dimension (m) showed different trends. Scale bars = 100 
μm129. 
Figure 42. Contractile velocities of hiPSC-CMs exposed to drug compounds. Short term 
changes to contraction motion waveform and average contraction velocities were observed in 
hiPSC-CMs treated (a, d) alfuzosin, (b, e) flecainide and (c, f) isoproterenol. (g, h) Long-term 
treatment of hiPSC-CMs with isoproterenol showed negligible changes in both contraction and 
relaxation velocities over a 7-day period129. 
Figure 43. Fractal changes on hiPSC-CM drug response. hiPSC-CMs was treated with 3 drugs, 
including (a) alfuzosin, (b) flecainide and (c) isoproterenol over a short period with incremental 
doses. The beat rate, capacity dimension and correlation dimension were compared respectively 
in response to the drug dosages. (d) A long-term drug study was also conducted by supplying a 
constant dose of isoproterenol over the course of 7 days129. 
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1. Chapter 1: Introduction  
 
1.1 Pluripotent stem cell engineering 
Stem cells have emerged over the past decades as powerful tools in research. The field of stem cell 
engineering encompasses many disciplines, including basic research, development of diagnostic 
and screening tools, and development of stem cell-based therapies. More specifically, human 
induced pluripotent stem cells (hiPSCs) have demonstrated promise in medical research fields. 
hiPSCs are genetically reprogrammed adult cells with capabilities to develop into any cell type 
with the proper induction factors. hiPSCs rose to prominence when Yamanaka et al. demonstrated 
that adult somatic fibroblast cells can be reprogrammed to become pluripotent1. This allows the 
cells to obtain unique characteristics that resemble embryonic stem cells (ESCs), which are found 
in embryos and are the origin of human development. The ability to recapitulate ESC phenotypes 
proposes tremendous potential to be implemented in in vitro modeling of cell and tissue 
development, from differentiation to tissue morphogenesis. In addition, hiPSCs are self-renewing, 
offering an unlimited source of cells that bypass controversies involved in ESC sourcing. These 
characteristics offer great potential for implementation of hiPSC tissue development as an in vitro 
model for in vivo human development (Figure 1).  
 
1.2 Pluripotent stem cell-based cardiac tissue engineering 
1.2.1 Advantages of pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) 
Diseases related to the heart are one of the most prominent worldwide. The extremely limited 
regenerative potential of the makes it especially susceptible to damage and failure. Tissue 
engineering approaches have been the strategy of interest for cardiac related regenerative 




medicine. Progress in cardiac tissue models has demonstrated extensive opportunities to engineer 
in vitro biologically optimized tissues for understanding disease mechanisms, formulating 
personalized therapies, and developing drug-screening platforms2–6. Cardiomyocytes are the 
primary cells that comprise the heart and are the main functional cells that produce heart 
contraction. Cardiomyocytes for cardiac tissue engineering were traditionally obtained by isolation 
from mammalian model organisms, most notably being from neonatal mouse or rat sources 
(nrCMs). The limitations of these cells are that these sources require time consuming isolation 
procedures each time the cells are needed. Additionally, primary cell isolation from rats presents 
a species barrier that cannot be reliably translated to human cardiac physiology7,8. By deriving 
cardiomyocytes from hiPSCs (hiPSC-CMs), we could continuously generate these highly 
functional cells at an unlimited capacity because of the regenerative capacity of hiPSCs to 
accelerate progress in this field.  
 
1.2.2  hiPSC-CMs for drug screening  
Drug-induced cardiac toxicity is one of the primary reasons for the failures of drug development 
pipeline and even post-clinical removal due to cardiac side effects after reaching the market (Liang 
et al., 2013). Recent advances in hiPSC technology have offered new insights into modeling 
cardiac tissue in vitro and screening drug-induced cardiotoxicity. Neonatal rat cardiomyocytes 
(nrCMs) are used as viable drug-screening platforms, but species differences present challenges in 
fully recapitulating human physiology and drug response7. It has been shown that beat rhythm was 
more stable in hiPSC-CMs compared to nrCMs, as well as high drug sensitivity and responsiveness 
of hiPSC-CMs9. Treatment of hiPSC-CMs with norepinephrine and isoproterenol produced 
changes in beat rate and contractility that was consistent with adult human heart slices, further 




suggesting the potential of hiPSC-CMs in screening for drug-induced cardiotoxicity10. With the 
development of heart-on-chip technologies, pharmacological studies on the cardiac 
microphysiological system showed that IC50 and EC50 values were more consistent with the data 
from tissue-scale references compared to cellular-scale studies11. 
 
1.2.3  hiPSC-CMs for three-dimensional cardiac tissue modeling  
Accurate cardiac tissue modeling using three-dimensional (3D) stem cell-based cardiac tissue 
engineering approaches primarily rely on direct cardiac differentiation from EBs12–14. EB-
mediated cardiac differentiation suffers from variability of EB size, organoid heterogeneity, and 
poor spatial organization15. The majority of in vitro cardiac tissue models based on hiPSC-CMs 
primarily focus on accurate recapitulation of physiologically relevant tissue structures of the adult 
human heart, which are generally achieved by populating pre-fabricated 3D biomaterial scaffolds 
with pre-differentiated hiPSC-CMs11,16–20. For example, in the biowire platform21, microfluidic-
based devices22, and cantilever systems23, cardiomyocytes were first differentiated from 
hiPSCs/hESCs in conventional tissue culture plates and then seeded as single cells or tissue 
clusters into the fabricated devices to form adult-like aligned cardiac muscle11,24. hiPSC-CMs often 
don’t exhibit phenotypes of mature cardiac tissue, because they are derived in vitro and are not 
subjected to the same degree of time or biomechanical factors that promote maturation. Many 
groups have focused on promoting 3D cardiac tissue alignment 3,11,16,20,25, which is a characteristic 
of mature cardiac tissue. This is because cardiac alignment is essential for modulating the electrical 
activity and population of cardiomyocytes to produce synchronized contraction function26. In 
addition, disordered alignment is associated with congenital heart disease and cardiomyopathies27. 




The advantages of these engineered cardiac tissue models are not only the structural mimicry of 
adult heart tissue, but also their capability of electromechanical measurements and simulations28,29. 
 
1.3 Stem cell organoids  
1.3.1  Stem cell organoids as models of dynamic tissue organization 
The adult-mimicking cardiac tissue model systems described above are designed to enhance the 
maturity and vascularization of hiPSC-CM tissues for the purpose of drug screening and disease 
modeling21,30–32. However, they are not designed for studying dynamic cellular self-organization 
occurring along with the cardiac differentiation process to study heart development since these 
cells are seeded and reconstructed after differentiation. As such, these approaches do not allow us 
to observe cell lineage specification and spatial self-organization during the cardiac development 
process. The proper functioning of the heart is essential for embryo development and survival, as 
it is the first organ to form and begins pumping blood even before valves and chambers are 
formed33. Therefore, understanding key biomechanical factors that drive the events involved in 
heart development are necessary to assess overall embryonic health. Organoids are thought of to 
have enormous potential in studying not only organogenesis of the heart, but many organ types 
within the body as well. Organoids are 3D tissues formed from the self-organization of cells to 
form key features of their represented organ34. They are composed of a self-renewing stem cell 
population that can differentiate into multiple cell types that exhibit cellular spatial organization 
and tissue functions comparable to the corresponding organ. These stem cell-based organoid 
systems, therefore can recapitulate events of early organogenesis.  
 
1.3.2  Engineering stem cell organoids  




Organ development is often thought to be directed by surrounding biochemical signals and 
biophysical cues in utero. 3D organoid technology is built upon fundamental concepts of 
developmental biology, which relies on dynamic multicellular self-organization to form functional 
biological tissues35. Conventional differentiation from hiPSCs and human embryonic stem cells 
(hESCs) were primarily conducted under 2D cell culture systems (6-well plates) without proper 
biophysical cues. Although this method is suitable for day to day hiPSC culture expansion, 
differentiated tissue on standard tissue culture surfaces ultimately lack region-specific structure 
and architecture seen in native tissue36. Monolayer hiPSC differentiation, therefore, does not 
accurately represent the complexity of morphogenetic events that comprise organogenesis2,37, 
which are governed by the synergistic interactions of biochemical and biophysical factors.  
 
Recently, there has been progress in stem cell organoid engineering to generate a wide range of 
miniature organ models resembling the brain38,39, kidney40, intestine41,42, and retina43 (Figure 2). 
Organoids are engineered by controlling the size and shapes of hiPSC colonies in order to promote 
self-assembly and self-organization of differentiating tissue. Organoids offer the benefit of 
recapitulating tissue morphogenesis into spatially organized 3D tissue to better understand 
developmental biology and for greater applicability in medication screening. Early organoid 
models relied on Matrigel scaffolds to encapsulate stem cell spheroids, which self-assemble into a 
functional organoid. However, since Matrigel is essentially extracellular matrix extracted from 
mouse cancer cells, this presents inherent heterogeneity between batches of Matrigel and limits 
the organoid reproduction consistency.  
 




Efforts to promote reproducible organoid formation has, therefore, been demonstrated through 
engineering fully defined synthetic materials that recapitulate natural extracellular matrix. Robust, 
and highly reproducible intestinal organoids have been achieved using synthetic hydrogel 
networks that not only support intestinal organoid culture, but also direct the differentiation by 
carefully defining the material properties of the hydrogels44–46. The controlled parameters include 
material chemistry, stiffness, and dynamics which can be fine-tuned to optimize the spatiotemporal 
organoid formation. Alternative approaches to synthetic material encapsulation include controlling 
the biophysical and biomechanical inputs. Microfluidic systems, for instance, has also been proven 
to guide spatial organization of differentiating PSCs. Using microfluidic devices, precise signaling 
can be induced to create differentiation domains of localized morphogen sources. This has been 
shown particularly in modeling embryonic development, such as in germ layer patterning47, as 
well as amniotic and epiblast layer formation48.  Particularly, biophysical input from geometric 
confinement has been employed to model in vivo gastrulation as well, where hPSCs were patterned 
and differentiated to form concentric rings indicative of a specific germ layer49–51(Figure 3). These 
examples illustrate the necessity of engineering spatiotemporally controlled cell 
microenvironments to guide the spatial organization of stem cell organoids of specific biological 
tissues. 
 
1.4 Cardiac organoid engineering 
Cardiac organoids have proven to be a challenge because of the complexity in the environmental 
conditions and cell compositions of the heart. This is especially the case for the developing heart 
due to the dynamic morphological and cellular changes during organogenesis. Many approaches 
assemble immature cardiomyocytes (either harvested from neonatal rats or derived from PSCs) 




into constructs or combine a heterogenous mixture of cardiomyocytes and a variety of stromal 
cells to create biomimetic cardiac organoids4,17,52,53(Figure 4). One of the first 3D cardiac tissue 
constructs that identified the model as cardiac organoids was developed by Lee and colleagues in 
2008. Using a balloon catheter and collagen-based molding, they developed a pumping organoid 
chamber system that modeled a functional heart ventricle. Voges et al developed a cardiac 
organoid platform that resembled fetal heart tissue with regenerative potential after 
injury.  Richards and colleagues developed cardiac organoids with self-organized vascular 
structures that exhibited fundamental cardiac tissue functions by combining cardiomyocytes, 
stromal cells, and endothelial cells (Figure 4a). Although these methods have proven applicability 
for areas such as drug screening and injury modelling, they ultimately lack in their ability to study 
an early developing heart because they do not incorporate the self-organization of differentiating 
PSCs that is characteristic of in vivo organogenesis. 
 
To date, very few cardiac organoids derived from the self-assembly of differentiating PSCs have 
been reported in literature. One of the first models to focus on cardiac organoids based on self-
organization during differentiation was the cardiac microchamber platform developed by Ma et 
al.54,55 and the Healy Lab (UC Berkeley) (Figure 4b). This method was able to engineer 3D tissue 
from 2D culture plates by confining hiPSC colonies into specific patterns. The cardiac 
microchambers were engineered using a cell micropatterning approach that combined 
photolithography, tissue culture surface modifications and selective etching of non-fouling agents 
to create patterns for long term tissue confinement. Cell micropatterning methods have enabled 
precise control over the cellular microenvironment (e.g., shape and size of cell colonies) that 
regulates cellular morphology and functions56–58. Commercially micropatterned substrates (e.g. 




CYTOO chips etc.) are available and have been explored50, but don’t offer the same flexibility of 
designing and fabricating diverse arrays of geometrical features. The novelty of cardiac organoids 
generated from cell patterning is that it integrated organoid concepts with cell micropatterning 
approaches to (1) promote the self-organization of 3D tissue structures to mimic early heart and 
organ formation; (2) supply biophysical cues during cardiac differentiation of hiPSCs to facilitate 
cellular polarity and spatial organization of cardiac tissue patterns; and, (3) reduce tissue 
heterogeneity to create a systematic and experimentally reproducible in vitro cardiac organoid 
model.  
 
Using this integrative approach, Ma and colleagues found that the confined cells in various 
geometries self-organized into a 3D architecture with region-specific tissue layers. Specifically, 
beating cardiac tissue was primarily localized to the pattern center, whereas stromal cell types were 
distributed at the edges within the perimeter of the patterns. This suggested that the biophysical 
constraints experienced by cells at the pattern perimeter was a potential inducer for the cells to 
follow a stromal or supportive cell type lineage. Cells at the center that were least susceptible to 
the physical contact, contrastingly formed beating cardiac tissue. The resulting tissue construct is 
a spatially organized tissue structure composed of supportive cells and cardiomyocytes, each 
localized to specific regions in the pattern. The clinical applicability of however, has not been 
explored, nor has the degree of recapitulation to native developing cardiac tissue. By answering 
these questions, the cardiac organoids can contribute to the field of organoid engineering, 
especially fulfilling needs in clinical applications, such as drug screening.  
 
1.5 Scope of dissertation 




This dissertation will primarily focus on the characterization, optimization and application of 
cardiac organoids that have potential to recapitulate early heart development. In addition, one 
chapter is focused on analytical tools to characterize cardiac contraction, specifically for drug-
induced cardiotoxicity. As a whole, this dissertation encompasses tools and methods for the 
advanced drug screening of cardiac physiology. The main goals of this dissertation are to: 1) 
perform exploratory studies to better understand how geometric confinement influences the 
formation of cardiac organoids; 2) apply the cardiac organoids as an embryotoxicity screening 
platform; 3) study cell compositions of cardiac organoids to better understand biological function 
of the cardiac organoids; and 4) apply sophisticated computational tools to advance the study 
cardiac drug response. Chapter 2 will focus on the methodology used to generate cardiac organoids 
for subsequent chapters. Chapter 3 discusses how cardiac organoid structure and functions are 
governed via exploration of various geometrical patterns. Chapter 4 explores the ability of this 
platform to be used as a potential application of embryotoxic drug screening, since the organoids 
are hypothesized to mimic an early developing heart. A single shape and size were chosen to 
generate organoids on a large scale for drug screening during differentiation, which mimics 
continuous drug exposure, or medication prescription, during pregnancy. Chapter 5 discusses more 
in-depth genomic characterization of the organoids using next generation sequencing analysis. 
This analysis will be used to identify cell populations that comprise the cardiac organoids. Chapter 
6 describes an analytical tool used to characterize drug-induced changes to cardiac contraction. 
Lastly, Chapter 7 will conclude this dissertation as well as discuss the future prospective of this 
work.   





Figure 1. Stem cell biology and human development. Potentials of using in vitro induced 
pluripotent stem cell biology to model in vivo human cell and tissue development.  





Figure 2. Stem cell organoids exhibiting spatial-organization and features that resemble 
native in vivo organs. Stem cell organoids with spatial organization and patterning have been 
engineered to model numerous organs including (a) brain39, (b) kidney59, (c) intestinal42, and (d) 
retinal43. All figures reproduced with copyright permissions.   





Figure 3. Stem cell organoids engineered through precise microenvironment control. (a) 
Intestinal organoids generated in synthetic PEG-4MAL hydrogels46; (b) microfluidic-controlled 
epiblast and amnion structures60; (c) micropatterning of human stem cells to model germ layer 
formation49. All figures reproduced with copyright permissions.  





Figure 4. Cardiac organoids derived from cardiomyocytes differentiated from human 
induced pluripotent stem cells. Various cardiac organoid models have been developed by 
researchers. (a) vascularized cardiac organoid17; (b) self-organized cardiac organoid 
microchamber54. All figures reproduced with copyright permissions.  




2. Chapter 2: Organoid generation methodology 
 
Overview 
This Chapter outlines the methodology used for generating and characterizing cardiac organoids. 
The method to generate organoids is based on tissue culture surface micropatterning that confine 
pluripotent stem cell colonies into a desired geometry. This confinement drives the cells to self-
assemble into a 3D tissue structure during differentiation into organoids. Organoids were 
characterized based on their contraction functions, tissue specifications and 3D tissue architecture. 
 
2.1  Motivation and background of method adaptation 
The Healy Lab at UC Berkeley created arrays of 3D cardiac organoids in which hiPSCs 
differentiated into cardiomyocytes only in the center of each pattern (e.g., 400-µm circle patterns) 
with myofibroblast-like cells forming at the perimeter54. The patterning approach consisted of 
poly(ethylene glycol) (PEG)-based grafting onto standard tissue culture polystyrene and selective 
shape-specific plasma etching by use of poly(dimethyl siloxane) (PDMS) stencils. PEG has been 
used in numerous cell patterning techniques to supply a non-biofouling surface that rejects protein 
adsorption and cell attachment, thus supplying selective regions for cell attachment and 
proliferation61–63. We implemented this PEG-based patterning approach described by Ma et al.54 
and Hoang et al.55 and differentiate patterned hiPSCs into cardiac organoids and characterize their 
morphology, uniformity, and contractility. Unless otherwise specified, all experiments in 
forthcoming chapters were based on the methodologies implemented in this chapter. A schematic 
of the procedure from soft lithography to cardiac differentiation is illustrated in Figure 5a. 
 




2.2  Fabrication and micropatterning of tissue culture substrates 
2.2.1  Fabrication of patterned silicon wafer and PDMS stencils 
Patterned wafers were fabricated using standard SU8 photolithography. First, photomasks of all 
different pattern shapes and sizes were designed on AutoCAD software and commercially printed 
at CAD/Art Services Inc. SU8 Master wafers with desired features were fabricated with standard 
photolithography following the photoresist manufacturer's instructions. To summarize the 
procedure, SU8-50 photoresist (MicroChem) was spin-casted at a specified speed to attain features 
100 μm in height. SU8 is a negative photoresist that cures upon exposure to UV light, and thus 
cannot be washed away with developer solution. The SU8 casted wafer was quickly exposed to 
high intensity UV light with the photomask on top to crosslink the features designed on the masks. 
The masks retain transparent features that allow UV penetration in the desired shapes and sizes. 
The wafers were then baked post-UV exposure and soaked in a developer solution to remove 
uncured photoresist. This standard process essentially creates a mold with raised features that will 
be used for fabrication of PDMS stencils. Furthermore, a silane solution (1H,1H,2H,2H-
Perfluorooctyltriethoxysilane; Sigma Aldrich) was vacuum deposited onto the wafers to increase 
the hydrophobicity of the wafer for easy removal of the stencils. 
 
Stencils were fabricated using standard soft lithography techniques. PDMS pre-polymer (Sylgard 
184) was mixed at a 10:1 wt/wt ratio of elastomer base to curing agent and the mixture is degassed 
under vacuum. A small amount (about 1 mL) of PDMS pre-polymer was poured onto each wafer 
and pressed down with a square piece of transparency plastic, cut to the size of the wafer (Figure 
5b). The transparencies are pressed down further by placement of glass slides on top and then the 
wafer-PDMS-transparency-glass construct is then clamped with large binder clips (Figure 5c). 




This allows the PDMS to spread throughout the array of patterns and create open holes 
corresponding to the features on the wafer. The constructs were placed in a 60 ºC oven overnight, 
and the cured stencils were peeled and cut to fit into a 35 mm tissue culture well (Figure 5d).  
 
2.2.2  PEG-based surface patterning 
To pattern tissue culture polystyrene, a thin solution of PEG is grafted and selectively etched using 
the PDMS stencils and oxygen plasma. The PEG solution is prepared by combining and vortexing 
150 mg PEG 1000 (Polysciences), 1.8 mL PEG (400) diacrylate (PEGDA) (Polysciences), 15.55 
mL isopropanol and 0.45 mL MilliQ water. 760 µL of the solution was grafted onto individual 
wells of a 6-well plate that was pretreated for three minutes with oxygen plasma. The grafted plates 
were exposed to high-intensity UV light to polymerize the PEG at the surface and leaving behind 
residual polymer. The residual polymer was then washed away with MilliQ water to obtain an 
optically clear surface. Next, the PDMS stencil was placed on top of the PEG-grafted surfaces, 
which leaves selectively exposed regions of PEG to be etched with oxygen plasma treatment 
(Figure 5e). The etching removes the PEG from these regions exposed by the stencils and creates 
biofouling patterns for cell attachment. The patterned surfaces with stencils still adhered were 
sterilized and coated with hESC-qualified Geltrex Matrix (ThermoFisher) for hiPSC attachment. 
To sterilize, each well was filled with 70% ethanol and allowed to sit for 1 hour under a biosafety 
cabinet. The remaining ethanol was aspirated and washed with phosphate buffered saline (PBS). 
Thin-gelling hESC-qualified basement membrane matrix (Geltrex) was added to each well, 
completing the surface patterning and preparation for cell seeding.   
 
2.3  Patterning and cardiac differentiation of hiPSCs 




2.3.1  Human iPSC culture maintenance and seeding 
Human iPSCs derived from healthy adults were cultured and expanded using standard pluripotent 
stem cell culture techniques. Our lab protocol specifically maintains hiPSCs on Geltrex coated 
plates in Essential 8 (E8) medium and passaging with Accutase dissociation reagent. E8 medium 
was changed daily to maintain cell health and viability. The cells were considered ready for 
passaging and seeding at approximately 80% confluence. The patterned and coated plates were 
incubated at 37ºC for 1 hour prior to cell seeding to activate proteins within the Geltrex matrix. 
The confluent hiPSCs were washed with PBS and incubated with Accutase dissociation reagent 
for 4 minutes until the cells were visibly detached. The cells were centrifuged, resuspended in E8 
medium supplemented with 10 µM Y27632 and seeded onto the patterned tissue culture plates at 
a seeding density of 0.4E6-0.7E6 cells. The range accounts for the different sizes that are to be 
explored in this aim, as well as the variable growth kinetics of each cell line. After 24 hours, the 
stencils inside the wells were carefully removed with sterile tweezers, leaving behind only the cells 
that have attached within the patterns. In addition, E8 media was changed to remove the Y27632. 
In most cases, with daily feeding of cells, hiPSC colonies were able to proliferate and fill patterns 
to confluency around 72 hours after seeding to begin differentiation.  
 
2.3.2  Patterned hiPSCs maintain pluripotency  
When the patterned hiPSCs reached confluency, we performed simple quality control experiments 
to ensure optimal differentiation capacity of the hiPSCs. Specifically, we performed 
immunofluorescence characterization to test for expression of pluripotent transcription factors and 
surface markers. The confluent patterns showed positive expressions of OCT4, SOX2, NANOG, 
E-cadherin, and SSEA4 that were distributed across all cells (Figure 6). This indicated that the 




patterned hiPSCs maintained their pluripotent potential and do not undergo uncontrolled 
spontaneous differentiation.  
 
2.3.3  Differentiation of patterned hiPSCs into cardiac organoids 
Cardiac differentiation was initiated approximately three days after initial seeding when the cells 
reached confluency in the patterns (Figure 7). Differentiation was performed via small molecule 
modulation of the Wnt/Beta date in pathway64 (Figure 8). Small molecule stocks were dissolved 
in sterile DMSO and diluted to their final concentrations in RPMI 1640 medium supplemented 
with B27 minus insulin (RPMI1640/B27-I). First, to initiate differentiation, the culture medium 
was exchanged with 10 uM GSK3 inhibitor CHIR99021 (Day 0) for 24 hours and then exchanged 
with fresh RPMI1640/B27-I on Day 1. On Day 2, the medium was exchanged with 5 uM of WNT 
pathway inhibitor IWP4 (Day 2) for 48 hours. On Day 4, the IWP4 was removed and replaced 
with fresh RPMI1640/B27-I. On Day 6 onward, the medium was changed to RPMI1640 
supplemented with B27 complete supplement (RPMI1640/B27+C) every two days until 
termination around Day 20. The patterned cells change morphology throughout differentiation, 
beginning as a 2D monolayer of hiPSCs self-assembling into a tissue structure that exhibits 
spontaneous contraction at around Day 10 of the differentiation timeline.  
 
2.4  Cardiac organoid function and 3-dimensional morphology 
2.4.1  Characterization of cardiac organoid contraction function 
The contraction function of cardiac organoids was characterized at or around Day 20 of 
differentiation (Figure 9a). The day of termination was determined based on visual examination 
of the overall quality of the cardiac organoids over time, as many cells began to die if cultured for 




too long, especially the cardiomyocytes. Before termination, contraction videos were recorded at 
a minimum of 50 frames per second for video-based contraction analysis. Organoids were imaged 
in an onstage microscope incubator (OkoLab Stage Top Incubator, UNO-T-H-CO2) at 37 ˚C and 
5% CO2 to maintain standard physiological conditions on a Nikon Ti-E inverted microscope with 
Andor Zyla 4.2+ digital CMOS camera. The videos were exported as single image sequences and 
analyzed using an open source Motion Tracking Matlab script developed by Huesch et al. The 
software implements block matching to compute motion vectors representing the motion velocities 
created by the contractile behaviors of the tissue. Furthermore, the motion vectors can be 
reconstructed into contraction motion waveforms that are representative of the muscle 
contraction/relaxation cycles of the tissues. Direct parameters that were exported were the 
contraction and relaxation velocities, beat rate, and beat duration.  
 
2.4.2  Characterization of cardiac organoid morphology 
Immunofluorescence staining was the primary method for characterization of cell type and tissue 
morphology, allowing analysis in both 2D and 3D. After video recording, samples were sacrificed 
and fixed with 4% (vol/vol) paraformaldehyde (PFA) for 10 minutes. After PFA treatment, 
samples were washed and permeabilized with 0.2% (vol/vol) Triton X-100, blocked with 2% 
(wt/vol) bovine serum albumin (BSA) and incubated with the appropriate dilution of primary 
antibodies for 1 hour at room temperature. After incubation, the primary antibody was removed 
and washed with PBS. Secondary fluorescent antibodies were then incubated in the dark for 2 
hours at appropriate dilutions and nuclei were tagged with 300 nM DAPI. The antibodies used 
consisted of at least three markers of terminal cardiomyocytes and at least three markers of smooth 




muscle (Table 1). Confocal microscopy (Zeiss U880) was used to capture z-stacks (8 um spacing 
between slices) of the organoids for height measurements and 3D reconstruction. 
 
The cardiac organoids were assessed based on three parameters that characterize the overall 
cardiac tissue distribution and 3D morphology (Figure 9b, c). All images were imported into 
ImageJ for image reconstruction and analysis. The Area Ratio was measured by using the circular 
or elliptical tool to approximate the area of fluorescence of tissue staining positive for cardiac 
tissue and normalizing this area relative to the area of the entire pattern. The Height was measured 
by locating the top and bottom of the organoids using confocal microscopy. Lastly, the FWHM 
was determined by measuring the tissue diameter at half of the organoid height.  
 
2.5  Cardiac organoid gene expression analysis  
On Day 20 of differentiation, cardiac organoids were sacrificed for RT-qPCR analysis. RNA was 
extracted using the RNeasy Mini Kit (Qiagen) and stored in -80 ˚C until needed. The RNA was 
then converted to cDNA using the Superscript IV First Strand Synthesis kit (Thermofisher). Genes 
of interest include cardiomyocyte-specific genes and stromal cell genes, plus TaqMan array of 
human factors for cardiogenesis (Thermofisher) (Table 2). PCR plates were prepared according to 
standard protocol provided by Thermofisher and then run using the QuantStudio 3 Real-Time PCR 
System. All data was normalized to the respective housekeeping genes that were run in parallel 








2.6  Statistical analyses  
All box plots show the minimum, maximum, median, and 25th and 75th percentiles. Unless 
otherwise stated, statistical analysis was performed based on analysis of variance (ANOVA) with 
Tukey’s multiple comparison test. 
  





Figure 5. Schematic of procedure and process of PDMS stencil fabrication 
(a) Schematic outlining key steps of the entire procedure. (b) SU8 master with a small amount of 
PDMS prepolymer. (c) Completed assembly of the patterned SU8 master-PDMS-transparency-
glass slide construct. (d) Thin film of PDMS removed from the assembly after curing and then 
placed on top of the optically clear PEG grafted surface (e). Figure reproduced from Hoang et al. 
2018 Nature Protocols55. 
 
  





Figure 6. Quality control of patterned hiPSC pluripotency. The micropatterned hiPSC colonies 
maintained the expression of pluripotency markers of (from left to right) OCT4, NANOG, E-
cadherin, SOX2, and SSEA4. Scale bar, 200 µm.  





Figure 7. Confluent micropatterned hiPSC colonies. Bright-field microscopy images of arrays 
of micropatterned hiPSCs with different sizes and shapes. Scale bar, 400 µm. Clockwise: 200 µm 
circles, 400 µm circles, triangles, and 600 µm circles.  
  





Figure 8. Cardiac differentiation timeline to generate cardiac organoids. Patterned cell 
morphology changes from 2D monolayer of cells (D0) into 3D tissue (D6 onward) throughout 
differentiation; scale bars 600 µm. 
  





Figure 9. Cardiac organoid function and structure characterization. (a) Motion tracking 
analysis based on vector computation of pixel movement generates contraction velocity 
waveforms representing beat cycles of the cardiac organoids. (b) Immunofluorescence staining 
used to compute the Area Ratio, which is the area of cardiac tissue (cTnT) coverage relative to the 
area of the entire pattern. (c) Confocal imaging was used to capture z-stacks of the tissues, which 
were reconstructed for 3D morphological scoring of the height and full-width at half-maximum 
(FWHM). Scale bars 200 µm. 
  
a b c 




Table 1. List of primary and secondary antibodies used for immunofluorescent staining and 
imaging 
  
Primary antibodies (species) Vendor Catalog No. Dilution 
Cardiac troponin T (mouse) Thermo Fisher Scientific MS295P 1:200 
Sarcomeric α-actinin (mouse) Sigma-Aldrich  A7811 1:300 
Myosin heavy chain (mouse) Abcam Ab97715 1:200 
Cardiac troponin I (rabbit) Abcam Ab47003 1:200 
Vimentin (mouse) Thermo Fisher Scientific MA5-11883 1:100 
α-SM22 (rabbit) Abcam Ab14106 1:300 
Calponin (rabbit) Abcam Ab46794 1:200 
α-Smooth muscle actin (rabbit) Abcam Ab5694 1:100 
OCT4 (rabbit) Abcam Ab18976 1:200 
NANOG (mouse) Thermo Fisher Scientific MA1-017 1:100 
SSEA4 (mouse) Stem Cell Technologies 60062 1:200 
SOX2 (rabbit) Thermo Fisher Scientific PA1-094 1:100 
E-cadherin (mouse) Abcam Ab1416 1:200 
Secondary Antibodies 
   
Alexa Fluor 488 goat anti-
mouse IgG 
Thermo Fisher Scientific A-11029 1:200 
Alexa Fluor 546 goat anti-
mouse 
Thermo Fisher Scientific A11003 1:200 
Alexa Fluor 488 goat anti-
rabbit IgG 
Thermo Fisher Scientific  A11008 1:200 
Alexa Fluor 546 goat anti-
rabbit 
Thermo Fisher Scientific A11010 1:200 
 




Table 2. TaqMan arrays used for gene expression analyses 
  
Taqman Assay ID Gene/Array Name Taqman Assay ID Gene/Array Name 
Hs00155658_m1 ACVR2A Hs00177373_m1 MAP3K7 
Hs00609603_m1 ACVR2B Hs00176247_m1 MAPK14 
Hs00181051_m1 APC Hs00231149_m1 MEF2C 
Hs00153179_m1 ATF2 Hs01101425_m1 MYH6 
Hs00394718_m1 AXIN1 Hs01110632_m1 MYH7 
Hs00205566_m1 BMP10 Hs00293096_m1 MYH7B 
Hs00154192_m1 BMP2 Hs00166405_m1 MYL2 
Hs00370078_m1 BMP4 Hs04187281_m1 MYL4 
Hs00233476_m1 BMP7 Hs00231763_m1 NKX2-5 
Hs01034913_g1 BMPR1A Hs00415443_m1 NODAL 
Hs00176144_m1 BMPR1B Hs00276431_m1 NOX4 
Hs00176148_m1 BMPR2 Hs00383231_m1 NPPA 
Hs01026536_m1 CCNE1 Hs00173590_m1 NPPB 
Hs00372959_m1 CCNE2 Hs01065279_m1 PECAM1 
Hs00154374_m1 CDC6 Hs00176973_m1 PRKCA 
Hs00270923_s1 CEBPB Hs00176998_m1 PRKCB 
Hs00193796_m1 CER1 Hs01090047_m1 PRKCD 
Hs00175141_m1 CHUK Hs00178455_m1 PRKCE 
Hs00959434_m1 CNN1 Hs00177010_m1 PRKCG 
Hs00355045_m1 CTNNB1 Hs00702254_s1 PRKCI 
Hs00183740_m1 DKK1 Hs00989970_m1 PRKCQ 
Hs00737028_m1 DVL1 Hs00177051_m1 PRKCZ 
Hs00153451_m1 E2F1 Hs01078066_m1 RB1 
Hs00231667_m1 E2F2 Hs00195432_m1 SMAD1 
Hs00605457_m1 E2F3 Hs00183425_m1 SMAD2 
Hs00608098_m1 E2F4 Hs00929647_m1 SMAD4 
Hs00231092_m1 E2F5 Hs00195437_m1 SMAD5 
Hs00242501_m1 E2F6 Hs00195441_m1 SMAD9 
Hs00266645_m1 FGF2 Hs01038777_g1 TAGLN 
Hs00268943_s1 FZD1 Hs01385457_m1 TBX18 
Hs00273077_s1 FZD10 Hs00911929_m1 TBX2 
Hs00184043_m1 FZD3 Hs00396596_m1 TBX20 
Hs00201853_m1 FZD4 Hs01052563_m1 TBX5 
Hs00361869_g1 FZD5 Hs00413032_m1 TCF3 
Hs00171574_m1 FZD6 Hs01009038_m1 TCF7L2 
Hs00275833_s1 FZD7 Hs02339499_g1 TDGF1 
Hs00259040_s1 FZD8 Hs00998133_m1 TGFB1 
Hs00171403_m1 GATA4 Hs00234244_m1 TGFB2 
Hs01053355_m1 GNAI1 Hs01086000_m1 TGFB3 
Hs01064686_m1 GNAI2 Hs00610318_m1 TGFBR1 
Hs00197803_m1 GNAI3 Hs00234253_m1 TGFBR2 
Hs00387073_m1 GNAQ Hs00165957_m1 TNNI3 
Hs00255603_m1 GNAS Hs00943911_m1 TNNT2 
Hs01564092_m1 GNB3 Hs00958111_m1 VIM 
Hs00275656_m1 GSK3B Hs00182986_m1 WNT11 
Hs99999908_m1 GUSB Hs00263977_m1 WNT3A 
Hs00231848_m1 HAND1 Hs00230534_m1 WNT8A 
Hs00232769_m1 HAND2 Hs00610126_m1 WNT8B 
Hs00167041_m1 HNF1A Hs01103751_m1 WT1 
Hs01001602_m1 HNF1B 
 








The goal of this chapter is to assess different confinement conditions and determine which 
geometries would yield optimal and efficient generation of cardiac organoids. This chapter 
describes the various shapes used to perform this particular study, where our goal was to assess 
how the geometry directs the differentiation of cardiac organoids. Previously, cardiac organoids 
were primarily generated in circular shapes, which demonstrated that the biophysical stresses from 
the constraint produced supportive cell types that were localized along the pattern perimeter. 
Therefore, we hypothesized that shapes with angular geometries can provide greater biophysical 
stress and will influence the cell specification trajectories of the cardiac organoids. The influence 
of the polygonal geometries was first assessed by studying the formation of organoids in circular, 
triangular and square shapes. Then, we assessed the influence of size on the differentiation of the 
organoids. From these data collected, we evaluated how geometry and size affects the 3D tissue 
morphology and cardiac functions of cardiac organoids.   
 
3.1  Background and rationale 
Cell patterning methods to create specific geometric conditions have been used extensively to 
govern the morphogenetic events of 3D tissue formation54,65–69. These studies have shown that 
stem cell differentiation can be driven by pattern geometry, where a specific shape can favor 
differentiation into a particular cell type. In addition, studies modelling mammalian development 
have also demonstrated the spatial differences of cell proliferation and differentiation between 




pattern center and perimeter due to the mechanical stress presented by geometric confinement50,70. 
These studies suggest that tissue formation and cell specification is highly governed by biophysical 
factors as well as structure–function relationships that drive developmental processes. Thus, 
models of 3D tissue morphogenesis should consider tissue geometry and mechanical stress as 
inductive cues for spatial tissue organization during differentiation.   
 
This chapter discusses an exploratory study design where various shapes were used to generate 
cardiac organoids. These shapes include circular, triangular, and square geometries scaled to the 
same area as a 400 µm diameter circle. In addition, we assessed shape size by generating cardiac 
organoids in circles ranging from 200 um - 1000 um in diameter. Photomasks for the respective 
patterns were designed using AUTOCAD and fabricated as per procedure described in Chapter 2.  
 
3.2  Shape confinement on cardiac organoid development, function, and morphology 
3.2.1  Cardiac organoid structure 
Cardiac organoids were generated using the methodology described in the previous chapter. First, 
using circular organoids, we verified the cardiac specification through immunofluorescent staining 
at different differentiation stages. There was positive expression of mesoderm marker BRA on 
Day 1, and cardiac progenitor markers NKX2.5 and GATA4 on Day 10, indicating a transition 
from pluripotency to the appropriate cardiac specification (Figure 10a). This approach generated 
robust contracting cardiac organoid arrays of 50-100 organoids within 20 days. We found that 
cardiomyocytes were primarily differentiated on the center top of the organoids, demonstrated by 
multiple cardiac-specific markers (Figure 10b): cardiac troponin T, myosin heavy chain β, 
sarcomeric α-actinin, and cardiac troponin I, while smooth muscle-like stromal cells distributed 




along the pattern perimeter, indicated by positive expression of α-smooth muscle actin, calponin, 
α-SM22, and vimentin (Figure 10b).  
 
3.2.2  Shape influence on organoid contractile functions and structure 
The study design consisted of comparing organoid generation from three pattern shapes (circle, 
square and triangle) with the same scaled area (Figure 11a). We found that cardiac organoids from 
circular patterns exhibited significantly higher contraction velocity, lower average beat rate, and 
longer beat duration (Figure 11b-d). Circles also produced the organoids with larger area ratios 
than squares and triangles (Figure 11e). For 3D tissue morphology, the cardiac organoids from 
triangle and square patterns were consistently lower in height and FWHM than the circles. Thus, 
the polygonal geometries inhibited the capacity of the cells to form organoids with comparable 
structural integrity to the circular organoids (Figure 11f, g). These observations illustrate that the 
development of cardiac organoids is affected by the pattern shape, in which the angular geometry, 
like triangles, presents high physical constraint to the cells.  
 
We hypothesized that polygonal constraint promotes a higher degree of differentiation into the 
stromal cell types, rather than cardiomyocytes. We plotted the structure-function correlations and 
observed a decline in the contraction rate that corresponded to the increasing area ratios (Figure 
11h). This demonstrated an inversely proportional relationship between the cardiac tissue size and 
the contraction rate. The decline in contraction rate can be attributed to higher contraction 
velocities exhibited by the circular organoids, since larger muscle tissues and robust contraction 
results in the tissues taking longer to contract. From the structure-structure correlations (Figure 
11i), we observed that triangular organoids were clustered with smaller values of height and 




FWHM, while circular organoids were generally larger in these aspects, which correlates to 
increased tissue volume. Overall, the circular pattern geometry promoted more robust formation 
of cardiac organoids with large size and high contractile functions.  
 
3.3  Size confinement on cardiac organoid development, function, and morphology 
3.3.1  Cardiac organoid function and structure is limited by size 
To examine the effects of pattern size on cardiac organoid development, we generated organoids 
in circular patterns ranging 200 – 1000 µm in diameter (Figure 12a). The 200 μm patterns did not 
reliably produce the organoids consistently or efficiently. The percentage of patterned hiPSC 
colonies of 200 μm circles that were able to successfully form organoids was very low (~ 20%), 
in comparison to all other sizes where the efficiency was approximately 80%. We found no 
significant differences on beat rate (Figure 12b), contraction velocities (Figure 12c) and beat 
duration (Figure 12d) among different pattern sizes, with the exception of the 200 μm organoids 
due to the inconsistent differentiation capacity of this size. For the remaining sizes, this indicated 
that size did not significantly affect the contractile functions of cardiac organoids.  
 
In contrast, the pattern size had apparent effects on morphology and architecture of the organoids. 
The circles with 200 µm diameter produced the cardiac organoids with the largest area ratio of 
cardiac muscles amongst all the circle sizes, albeit with the largest variability as well (Figure 12e). 
Regarding the circles with large sizes (800 µm and 1000 µm), these patterns produced the 
organoids with a greater area ratio (> 0.60) in comparison to the 400 µm and 600 µm circles (~ 
0.50). Despite the larger cardiac muscle distribution of the larger circles, the organoid height was 
much lower on these larger circles compared to 400 µm and 600 µm circles (Figure 12f). 




Additionally, the FWHM steadily increased with increasing pattern size, peaked at 600 μm 
patterns, and decreased with larger sized circles (Figure 12g), indicating the greatest 3D 
architecture of the cardiac organoids at 600 μm.  
 
The structure-function relationships for the cardiac organoids showed clusters of organoids with 
pattern size larger than 400 µm, indicating the consistency in the organoid production. Instead, 
200-µm organoids showed a much more scattered distribution of structure-function relationship, 
corresponding to faster beat rate and larger size. However, independent of the size increase from 
400 µm to 1000 µm in diameter, the area ratios of these cardiac organoids remained consistent, 
which in turn produced organoids with comparable contractile function (Figure 12h). Regarding 
the 3D architecture of the cardiac organoids, a clear cluster separation of 600-µm organoids from 
other pattern sizes showed largest values of height and FWHM (Figure 12i). These results suggest 
that larger patterns do not further promote the cell assembly into a 3D structure with a significant 
reduction in 3-dimensionality of the cardiac organoids. It is inferred that as the pattern size 
increases further, the tissue formation begins to resemble that of 2D cardiac differentiation from 
hiPSCs. Overall, the pattern sizes have prominent effects on the structure and morphology of 
cardiac organoids, but less on the contractile functions. 
 
3.3.2  Organoid size influences cardiogenic gene expression 
To study how geometric confinement affected the cell fate choice of cardiac organoids, we profiled 
the gene expression of organoids with 200 μm, 600 μm, and 1000 μm diameter patterns (Figure 
13a). We found up-regulation of cardiomyocyte-specific markers (MYH7, MYH7B, MYL2, 
Nkx2.5, MYL4, and TNNI3) and down-regulation of stromal cell markers (TAGLN and CNN1) 




in large pattern sizes (600 µm and 1000 µm diameter circles) (Figure 13b). This data supported 
our previous contractile, structural, and morphological analyses, where cardiac differentiation and 
contractile functions were more robust in the organoids of larger pattern sizes. We also found that 
PRKC-related genes were highly expressed in the 200 µm organoids, attributing to the smooth 
muscle phenotype promoted by the geometric confinement71–73 (Figure 13c). In addition, BMP10, 
FGF2, FZD10, TBX18, and WT1 were also upregulated in 200 μm organoids, suggesting that 
small pattern size promoted the differentiation into possibly epicardial or epithelial stromal 
progenitor cells74,75. In contrast, genes of BMP7, HNF1B, NPPA, and SMAD9 were upregulated 
in 1000 µm patterns, which possibly indicated a greater degree of cardiac growth and 
morphogenesis, as these genes are involved in the pathways critical to the later stages of cardiac 
chamber formation76–78, and dysregulations in these pathways have resulted in cardiac defects79,80.  
 
3.4  Conclusions and discussion 
In this study, we were able to generate the cardiac organoids from various pattern sizes and shapes 
and found prominent impact from the geometric confinement on organoid morphology and 
functions. The high compactness that the cells may be experiencing within the geometries of small 
size or polygonal corners resulted in a higher degree of differentiation into stromal cell population, 
other than cardiac muscles, which in turn affected the tissue morphology and contractile functions. 
Research in cardiac tissue engineering has exploited the co-dependency of tissue structure and 
function, such that the structure of engineered tissues would have a profound effect on the capacity 
of the tissue to perform their desired functions6,26. Such structure-function correlation of cardiac 
tissues has been studied as early as the first several demonstrations of growing cardiomyocytes in 
defined anisotropic geometries81. The combination of tissue engineering and organoid technology 




provides the versatility and capability to generate the cardiac organoids of desired architectures 
with enhanced contractile functions, which can be useful in the design principles for organoid 
engineering.    





Figure 10. Differentiation from pluripotency into cardiac organoids. (a) 24h after CHIR 
treatment, patterned hiPSCs express mesodermal marker brachyury. (d) On Day 8 of 
differentiation, cardiac organoids express ISL1, followed by (d) NKX2.5 and GATA4 on Day 10, 
indicative of early cardiac progenitor cells; scale bars 200 µm. (b – top row) The spatial-organized 
cardiac organoids showed cardiac muscle on the top center with cardiomyocyte-specific proteins 
(cardiac troponin T (cTnT), β myosin heavy chain (MHC-β) sarcomeric α-actinin and cardiac 
troponin I (cTnI)) and smooth muscle-like cells on the perimeter of the organoids with stromal cell 
markers (smooth muscle actin (α-SMA), calponin, transgelin (α-SM22) and vimentin). Scale bar, 
200 µm. (b – bottom row) confocal microscopy images of cardiomyocytes on the cardiac 
organoids. Scale bar, 50 µm. 
  





Figure 11. Geometry effect on cardiac organoid function and structure. (a) Confocal 
reconstructions of cardiac organoids generated in circular, triangular, and square shapes; scale bars 
200 µm. From comparison of contraction function of cardiac organoids as influenced by shape 
geometry, (b) triangular and square organoids exhibited significantly decreased contraction 
velocity (n ≥ 10, *p = 0.0024), but (c) significantly faster beat rate (n ≥ 9, *p ≤ 0.0001) with (d) 
longer beat duration (n ≥ 9, *p ≤ 0.0001) relative to circular organoids. Structural 3D 




morphological scoring of cardiac organoids showed that circle shapes produced organoids that 
were significantly larger in area ratio (n ≥ 16, *p ≤ 0.0001) than triangle and square organoids. 
Only triangle organoids produced significantly decreased tissue height (n ≥ 9, *p = 0.0013) and 
both triangular and square organoids had significantly smaller FWHM (n ≥ 9, *p ≤ 0.0001). (h) 
Structure-function correlation plot illustrating the effect of structure on cardiac contraction. (i) 
Structure-structure correlation plot illustrating shape influence on 3D architecture. In all panels, 
box plots show the minimum, maximum, median, and 25th and 75th percentiles, and statistical 
analysis was performed based on analysis of variance (ANOVA) with Tukey’s multiple 
comparison test. 
  





Figure 12. Pattern size effects on cardiac organoid characteristics. (a) Cardiac organoids 
generated from the circular patterns with different sizes (200 µm – 1000 µm in diameter) showed 
spatial-organization of cardiomyocytes and stromal cells and 3D dome-shape in the X-Z plane. 
Scale bar, 200 µm. Contractile motion analysis showed no significant differences in contraction 




velocity amongst the cardiac organoids generated from different pattern sizes, but 200-µm patterns 
generated the organoids with significant differences in beat rate and beat duration comparing to 
the other pattern sizes (n = 10, *p < 0.0001 for beat rate; *p < 0.0001 for beat duration). The area 
ratio between cardiomyocyte staining and entire pattern size showed significant larger coverage 
but higher variation in cardiac muscle differentiation on the cardiac organoids generated from the 
patterns with 200 µm, 800 µm and 1000 µm diameter (n = 9, *p ≤ 0.0001 between 200 µm and 
400/600 µm; *p ≤ 0.0001 between 400/600 and 800/1000 µm). The cardiac organoids generated 
from 600-µm diameter circles exhibited better 3D morphology with largest values in (f) height (n 
= 8, *p = 0.0126 between 200 µm and 600 µm; *p = 0.0126 between 600 and 800/1000 µm) and 
(g) FWHM (n = 8, *p ≤ 0.0001 between 600 µm and 200/400 µm; *p ≤ 0.0001 between 600 and 
800/1000 µm). (h) Structure-function correlation plot for the cardiac organoid generated from 
different pattern sizes showed close clustering of the circular patterns of 400 – 1000 µm diameters, 
except for 200 µm diameter. (i) Structure-structure correlation plot showed that 600-µm diameter 
circular pattern consistently produced the cardiac organoids with the largest 3D structure. (j) Gene 
expression analysis showed that larger pattern sizes (600 µm and 1000 µm diameter circles) were 
associated with high expression of cardiac muscle-related genes, while small pattern (200 µm 
diameter circle) was associated with high expression of stromal-related genes. In all panels, box 
plots show the minimum, maximum, median, and 25th and 75th percentiles, and statistical analysis 
was performed based on analysis of variance (ANOVA) with Tukey’s multiple comparison test. 
 
  





Figure 13. Gene expression patterns directed by pattern size. (a) Gene expression heatmap of 
104 genes assayed the cardiac organoids generated from 200 µm, 600 µm, and 1000 µm – diameter 
circular patterns. (b) Gene expression of cardiac-specific and smooth muscle/stromal genes 
normalized to the expression of GAPDH housekeeping gene. (c) The signaling-related genes 
showed highly differentiated expression.  








This Chapter discusses the use of cardiac organoids as a drug screening platform, specifically for 
drug toxicity during fetal development. Since the organoids are derived from pluripotency and 
represent self-organizing cells during differentiation, it is assumed that they better mimic immature 
cardiac tissue that possesses early developmental phenotypes. Using this model, nine drugs were 
screened, and the toxicity was measured via assessment of inhibition to the contraction functions 
and tissue structures. The cardiac organoid model was also compared to danio rerio zebrafish 
embryos as an in vivo model of heart development. By cross comparison of both models, this 
Chapter concludes with advantages and limitations of both methods regarding embryotoxicity 
screening.  
 
4.1  Background and rationale 
At the end of 2014, the FDA removed the pregnancy category system from drug product labeling 
since it did not accurately communicate a medications’ degree of fetal risk. Certain medications 
administered during pregnancy have been attributed to cause adverse effects on fetal development. 
However, many drugs are still not well understood regarding their effects on human organogenesis. 
As a result, pharmaceuticals are often completely avoided during pregnancy due to possible, but 
uncertain risks. This leads to essential medications, like antidepressants and chemotherapeutics, to 
be withdrawn, despite the benefits to the mothers’ health, because the risks on fetal development 




are unclear. Regardless, nearly 40% of pregnant women in the US receive a drug from category C 
each year, while as many as 280,000 pregnant women are exposed to drugs (category D or X) with 
clear evidence of potential fetal risk. As such, about 2 to 3% of all birth defects result from drugs 
that were taken to treat a disorder or symptom82. The most commonly reported birth defects are 
heart related, and the potential for generating cardiac defects is of utmost concern when 
determining fetal drug safety. During embryogenesis, the heart is the earliest functional organ to 
form, exhibiting contraction and pumping blood as early as Day 22 of human development. 
Because of this naturally occurring milestone event in human development, it is acceptable to 
hypothesize that disruptions in heart development bears the possibility of resulting in gross fetal 
defects, allowing us to predict overall embryonic health. Thus, there is a need to establish a basis 
that recapitulates human myocardium development for effective recapitulation of heart 
development.  
 
Numerous vertebrate model organisms have been utilized to screen for teratogenicity, including 
whole rodent83, frog84, and zebrafish85,86 embryonic tests. However, predicting teratology using 
whole embryo screening has serious drawbacks, including differences in pharmacokinetics and 
metabolic pathways between species83. To overcome these challenges, researchers have developed 
sophisticated in vitro alternatives to reduce the complexity, cost and time associated with whole 
embryo screening to more efficiently screen for developmental toxicity. The mouse embryonic 
stem cell test (mEST)87, an in vitro developmental toxicity assay using cardiac differentiation, has 
been adopted by a number of pharmaceutical companies as a tool to assess the embryotoxicity of 
drug candidates at the early stages of drug development88. More recently, hiPSCs have been 
proposed to replace the mEST for better teratogenic predictions by overcoming the species barrier 




that has always posed limitations in traditional drug screening89. Advances in hiPSC technology 
have demonstrated potential solutions because not only do they have the capability to differentiate 
into almost any cell type, these cells can be patient specific, which opens opportunities for 
personalized medicine and more precise diagnostics. Additionally, hiPSC-derived tissues exhibit 
characteristics of early developmental lineage. For example, pluripotent stem cell derived 
cardiomyocytes are smaller in size, develop less mitochondria, and do not display aligned 
sarcomeric structures, which are all indications of early immature cell phenotypes30. Because of 
this unique characteristic, hiPSC-derived tissue has the potential to serve as a versatile tool to study 
and recapitulate events of tissue development. 
 
4.2  Experimental procedure to mimic fetal drug exposure  
From the results illustrated in Chapter 3, the optimal shape to produce cardiac organoids were 
circles of 600 um diameter. Organoids of this shape and size had consistent and robust contraction 
physiology, as well as the largest 3D architectures and were, therefore, determined to be the most 
reliable for larger scale drug screening studies. The cardiac differentiation protocol was modified 
to include the continuous supplement of drugs beginning at Day 1, 24 hours after treatment of 
GSK3 inhibitor CHIR99021, of the differentiation timeline (Figure 14a) and supplemented for the 
entirety of differentiation until termination for analysis. Drug supplementation during this period 
applies to all differentiation events specific to cardiac differentiation and also mimics continuous 
drug exposure during pregnancy. Concentrated drug compound stock solutions were dissolved in 
either DMSO or MilliQ water depending on their solubility. Stocks were further diluted into 
working concentrations in the corresponding culture mediums. In total, nine drug compounds were 
tested and analyzed at three concentrations each, along with a vehicle control. The drugs used are 




listed in Table 3 and range in safety from Categories A to X, as determined by the previously 
established FDA pregnancy category system. Drug concentrations were arbitrary, but chosen 
primarily based on solubility in culture medium, as well as approximated around peak plasma 
concentrations. Concentrations were increased by a factor of 10 for each incremental dosage in 
order to assess extreme dosages to evaluate potential toxicity to the organoid development.  
 
4.3  Cardiac organoids as an in vitro assay of developmental toxicity 
4.3.1  Sensitivity of cardiac organoid toxicity response to well-established safe and toxic drugs 
Drug treatment concentrations were chosen based on peak plasma concentrations reported by 
public databases provided by the FDA (https://www.accessdata.fda.gov/scripts/cder/daf/), or 
through tested concentrations reported in literature. First, we compared two drugs between 
category A and category X, both as positive and negative controls (Figure 14 b, c). Doxylamine 
succinate is clinically prescribed as a sleeping aid and is widely accepted drug to safely prescribe 
during pregnancy, as it was established as a Category A medication. A typical 25mg oral dosage 
results in mean peak plasma concentration of ~125 ng/mL (approx. 0.5 µM)90. Thalidomide is 
clinically prescribed as an anti-inflammatory as well as treatment for myeloma and has a reported 
peak plasma concentration approximately ranging from 0.62 – 2.82 µg/mL (approx. 2.4 – 10 µM) 
in humans91. Thalidomide is widely accepted as a Category X drug, because of the well-known 
birth defects that were first discovered in the 1950s that tied back to the administration of this drug 
to treat morning sickness in pregnant women.   
 
We found that doxylamine succinate (Category A) at all concentrations tested, which were above 
the normal peak plasma concentrations, had no negative effect to cardiac tissue distribution (Figure 




14d). In contrast, thalidomide (Category X) had produced the abnormal cardiac organoids with 
less cardiac tissue coverage relative to the untreated controls (Figure 14e). Although doxylamine 
succinate showed no significant effect on the cardiac differentiation, this drug had a prominent 
effect on the cardiac contractile functions with lower contraction velocity and slower beat rate 
(Figure 14f, h). We hypothesize that these occurrences are a result of the inherent therapeutic 
properties of this drug, as doxylamine succinate is prescribed as a sleeping aid, which has relaxant 
effects and also prescribed as an analgesic to reduce muscle tension92. In contrast, there was no 
significant effect from thalidomide on the contraction velocity, though high concentration of drug 
dosage led to high variability in the beat rate (Figure 14g, i). More importantly, high concentration 
of thalidomide (100 µM) impaired the 3D morphology of the cardiac organoids with significantly 
lower height and FWHM relative to the controls and in comparison to minimal structural 
impairment seen with doxylamine succinate treatment (Figure 14j-m). This indicated that exposure 
of this well-known teratogen resulted in severe impairment to hiPSC differentiation and 
organization into 3D cardiac tissues, which confirmed that this organoid model was sensitive to 
the morphological defects as a result of drug exposure. 
  
4.3.2  Cardiac organoid sensitivity to Category B - Amoxicillin 
Next, we tested the cardiac developmental toxicity of the drugs from the other pregnancy 
categories. Amoxicillin (category B) (Figure 15) is a commonly prescribed antibiotic with a mean 
peak plasma concentration of approximately 6 µg/mL (approx. 16 µM) (FDA). Drug treatment 
ranging from 1-100 µM showed no apparent toxic effect on either structure or functions of the 
cardiac organoids at all three tested concentrations. Although there is a slight effect on the beat 
rate and beat duration, contraction velocities were not significantly impacted. In addition, the size 




and structure of the organoids was not impaired between controls and high concentration of 100 
µM.  
 
4.3.3  Cardiac organoid sensitivity to Category C - Rifampicin 
Rifampicin (category C) (Figure 16) is also an antibiotic used to treat tuberculosis and meningitis. 
Rifampicin administration in healthy adults can reach peak plasma concentrations ranging from 4-
32 µg/mL (approx. 4.8-39 µM) (FDA). Treatment to cardiac organoids showed severe 
developmental toxicity at a high concentration (100 uM) with no organoid formation. Specifically, 
cells were not able to survive at this concentration, indicating an increasing degree of cytotoxicity 
as the treatment concentration increased. This was especially seen at low and moderate 
concentrations where the area ratio, height, and FWHM show a gradual decrease in all variables 
relating to cardiac tissue formation.  
 
4.3.4  Cardiac organoid sensitivity to Category D – Doxycycline  
Doxycycline (category D) (Figure 17) is also an antibiotic used to treat a large variety of infections, 
such as skin, respiratory treatment, sexually transmitted etc. Administration of doxycycline 
produces a mean peak plasma concentration of 2.6 µg/mL (approx. 5.8 µM). Similar to rifampicin, 
doxycycline also resulted in severe impairment on cardiac differentiation and organoid formation. 
Effects of doxycycline, however, became apparent even at a moderate concentration of 10 µM. At 
10 µM, cardiac organoids failed to produce a dome-like cardiac tissue structure, but rather formed 
patch-like regions of cardiomyocytes. Because of this, the organoids were able to exhibit 
contraction at this concentration, but Area Ratio and FWHM measurements could not be made 
because there was no complete cardiac tissue structure. Also comparable to rifampicin, high 




concentration resulted in severe cytotoxicity, where cells died within 2 days after the drug was 
first introduced. Therefore, we classified this drug as highly toxic, since failed to create 3D 
organoids due to massive cell apoptosis at high concentrations. 
 
4.3.5  Cardiac organoid sensitivity to Category D – Lithium Carbonate 
Lithium carbonate (category D antidepressant) (Figure 18) exposure did not result in negative 
effects to the contractile functions of the cardiac organoids but exhibited minimal toxicity to the 
organoid formation measured by area ratio and FWHM. Surprisingly, exposure of lithium only 
showed mild developmental toxicity manifested as slight reduction in cardiac differentiation and 
organoid formation. No impairment was observed in contraction functions. However, lithium is 
known to have a very narrow window of therapeutic concentrations, and there has been a long 
debate of this drugs’ developmental toxicity, especially resulting in congenital heart defects93,94. 
 
4.3.6  Cardiac organoid sensitivity to Category D - Phenytoin 
Phenytoin (category D) (Figure 19) is prescribed as an anti-convulsant and muscle relaxant to treat 
seizures. Therapeutic plasma concentrations range from 10-20 µg/mL (approx. 40-80 µM) (FDA). 
Phenytoin exposure produced the cardiac organoids that were smaller than controls, but still 
maintained structural integrity. However, the cardiac organoids were larger, but stopped beating 
at a high concentration (100 uM), until the drug was removed to allow the organoids to recover 
the contractile functions. We believe that the cardiac tissues were larger at high concentration 
because the high concentration prevented contraction of the tissue, thus preventing tissue 
compaction over time. When the drug was removed and replaced with fresh media, the organoids 
began to contract after approximately one day. After equilibration over 3 days, the organoids at all 




concentrations exhibited comparable contraction physiology to controls. This confirmed that 
phenytoin did not impair cardiac tissue development, but rather inhibited the muscle contractility 
due to its muscle relaxant properties95,96.  
 
4.3.7  Cardiac organoid sensitivity to retinoids Category D – Tretinoin and Category X – 
Isotretinoin 
Tretinoin (also known as all-trans-retinoic acid, category D retinoid) (Figure 20) and isotretinoin 
(13-cis-retinoic acid, category X retinoid) (Figure 21) are both retinoic acid derivatives used to 
treat severe acne. Isotretinoin is a metabolite of tretinoin, but both drugs can be prescribed 
individually. Plasma concentration of tretinoin range from 1-3 ng/mL (approx. 0.01 µM), whereas 
the plasma concentration of isotretinoin ranges from 300-800 ng/mL (approx. 1-2 µM) (FDA). 
Although both drugs are similar, there is a high range in peak plasma concentrations. This, as well 
as the presumptive safety category can be attributed to the method of administration, where 
tretinoin is often prescribed as a topical gel, and isotretinoin is administered orally. Tretinoin 
treatment completely abolished the cardiac differentiation at the highest tested concentration of 10 
µM, but still produced the organoids with comparable height and overall size as controls. Since 
retinoic acid derivatives are known compounds to cause fetal toxicity, we also tested isotretinoin 
on the cardiac organoids. Similar to tretinoin, isotretinoin can produce large organoids at all tested 
concentrations, but totally abolished the cardiac differentiation at even lower concentration at 1 
µM. This implied that retinoids caused severe impairment to the cardiac differentiation, but did 
not interfere with the tissue growth.  
 
4.4  Embryotoxicity screening on developing myocardium of zebrafish embryos 




Last, we compared the developmental toxicity of these tested drugs between cardiac organoid 
model and zebrafish whole embryo culture (zWEC), a well-established toxicity assay with 
promising potential to screen for teratogenicity97,98. We used transgenic Tg(myl7:GFP) zebrafish99 
that express GFP only in cardiomyocytes, which allowed us to readily score myocardial 
development and heart tube looping at 48 hours post-fertilization (hpf)100 (Figure 22a). Live 
zebrafish embryos were collected and exposed to the identical drugs at identical concentrations 
used in the cardiac organoid assay. Consistent with the organoid model, exposure with doxylamine 
succinate (Category A) (Figure 22b) had negligible effect on the zebrafish embryonic heart 
development, as there was a significant proportion of embryos exhibiting normal D-looped heart 
across all the concentrations. However, the effects of thalidomide (Figure 22c) on zebrafish 
embryonic heart development were not as significant as what we observed in the organoid model. 
We found that the proportion of normal heart looping did not significantly decrease at higher 
concentrations of thalidomide.  
 
Several of the other drugs (Figure 23) tested also showed meager embryotoxic effects to the 
zebrafish embryos, including rifampicin (Figure 23b) and phenytoin (Figure 23d). Amoxicillin 
(Figure 23a), lithium carbonate (Figure 23c) and doxycycline (Figure 23e) showed moderate 
toxicity. In contrast, retinoic acid derivatives, tretinoin (Figure 23f) and isotretinoin (Figure 23g), 
caused severe defects to the zebrafish embryo heart development. At low concentration (0.1 μM), 
embryos had severe heart defects, including smaller size and abnormal morphology. At higher 
concentrations, the hearts failed to develop, as indicated by 0% of embryos expressing the GFP 
transgene. This result was comparable to effects that we observed in the organoid model, which 
was a lack of cardiac development at higher dose. Upon comparing the organoid model with the 




zWEC model, we saw developmental toxicity that was comparable for both systems for most of 
drugs (doxylamine succinate, amoxicillin, lithium carbonate, phenytoin, tretinoin, and 
isotretinoin). However, rifampicin, doxycycline and thalidomide showed distinct mismatch 
between these two model systems. We infer that this is due to a number of factors, including 
species differences, method of drug exposure, and differences in the range of effective treatment 
concentrations.   
 
4.5  Conclusions and discussion 
In this study, the cardiac organoid model allowed us to evaluate human-specific drug-induced 
developmental toxicity based on disruption of forming correct 3D organoid structures and 
developing normal cardiac contractile functions. By exposing the cardiac organoids to a range of 
drugs with different risk categories, we found an overall increase of teratogenic severity on cardiac 
organoid formation, corresponding to the increase of test concentrations, as well as the increase of 
risk category from A to X. Category D drugs (phenytoin, lithium, doxycycline and tretinoin) 
showed diverse effects on developmental toxicity. Three antibiotic drugs tested on the cardiac 
organoids showed increased developmental toxicity with the increase of their risk classification in 
the pregnancy category. Continuing testing another three category D drugs on the organoids, we 
found variations in the levels of developmental toxicity on both tissue morphology and contractile 
functions. Overall, these results verified that this cardiac organoid model was sensitive to the drug-
induced developmental toxicity, thus offering the capability of morphological scoring based on the 
3D tissue formation, which is often not available from other stem cell-based in vitro assays.   
 




Upon the comparison between human organoid model and traditional zebrafish whole embryo 
culture (zWEC) assay, we observed that three drugs (thalidomide, rifampicin, and doxycycline) 
resulted in opposed toxicological responses, where cardiac organoids manifested severe 
morphological impairment, while zebrafish embryos only showed mild effects. Thalidomide, a 
known teratogen commonly used as a positive control, has demonstrated variable effects in 
different embryotoxicity assays. The developmental toxicity of thalidomide on zebrafish embryos 
has been documented to stunt fin development and inhibit angiogenesis, but only with higher 
concentrations (at least double the highest concentration of our study)101,102. In a comparative 
study, a 2D hiPSC-based model demonstrated stronger embryotoxic responsiveness to thalidomide 
exposure than the mouse embryonic stem cell test (mEST), highlighting the differences in drug-
induced developmental toxicity due to the species differences88. Rifampicin and doxycycline, 
however, have not been extensively studied for the potential of developmental toxicity with new 
human-based screening methods, such as hESC or hiPSC tests. For instance, rifampicin was used 
as an up-regulator of CYP genes in the zebrafish and PSC-derived tissues to enhance drug 
metabolism103, without explicit characterization for its embryotoxic potential. On the other hand, 
doxycycline, commonly used as an inducer for Tet-ON activation, has shown to enhance hiPSC 
survival and renewal at low concentrations (< 20 μM)104. However, doxycycline has been 
documented to induce fetal loss in live mice after administration of the drug for Tet-ON 
activation105. Although we have presented a relatively simple experimental design to demonstrate 
the sensitivity and responsiveness of the cardiac organoid model to a variety of drugs, the drug 
concentrations can be tailored to match physiological concentrations in amniotic fluid that the 
developing human embryo would be exposed to.   





Figure 14. Cardiac organoid developmental toxicity to doxylamine succinate and 
thalidomide. (a) The timeline of cardiac organoid generation and continuous drug exposure. Epi-
fluorescent microscopy images of the cardiac organoids for comparison between untreated controls 
with (b) doxylamine succinate (category A drug) and (c) thalidomide (category X drug). The area 
ratio of cardiac muscle coverage showed (d) an increase with doxylamine succinate (n = 29, *p ≤ 
0.0001), but a decrease with thalidomide at high concentrations (n ≥ 28, *p ≤ 0.0001). The 
contraction velocity of cardiac contractile motion showed no drug effect from (f) either 
doxylamine succinate (g) or thalidomide. The beat rate showed (h) a decrease with doxylamine 
succinate (n ≥ 9, *p ≤ 0.0001), and an increase with thalidomide at 1 µM and 10 µM concentrations 
(n ≥ 12, *p ≤ 0.0001). (j) The cardiac organoids under doxylamine succinate exposure showed no 
drug effects on the 3D organoid morphology at all the tested concentrations. (k) Thalidomide 
exposure induced significant structural impairment on 3D organoid formation, showed as lower 
height (n ≥ 9, *p ≤ 0.0001) and FWHM (n ≥ 14, *p ≤ 0.0001) at high concentrations. Representative 
confocal microscopy images of the cardiac organoids of (k) untreated control and (m) 100 µM 
thalidomide exposure showed severe abnormal organoid formation for quantitative morphological 
scoring.  





Figure 15. Developmental toxicity assay of cardiac organoids in response to treatment with 
Amoxicillin (Category B). Amoxicillin showed moderate toxicity with decreased beat rate (two-
way student t-test, n ≥ 11, *p = 0.0048) and increased beat duration (two-way student t-test, n ≥ 
11, *p = 0.0013) at high concentrations. Amoxicillin treatment at low concentrations, however, 
produced smaller cardiac tissues in area ratio (two-way student t-test, n ≥ 18, *p = 0.0083 between 
Controls and 1 µM) and in height (two-way student t-test, n ≥ 7, *p ≤ 0.0001). 
  





Figure 16. Developmental toxicity assay of cardiac organoids in response to treatment with 
Rifampicin (Category C). In all assays, cardiac organoids failed to differentiate at 100 µM 
treatment, and toxicity was also observed in contraction velocity (two-way student t-test, n ≥ 12, 
*p = 0.0174), beat rate (two-way student t-test, n ≥ 12, *p = 0.0232), area ratio (two-way student 
t-test, n = 29, *p = 0.0123), height (two-way student t-test, n ≥ 10, *p ≤ 0.002 relative to controls) 
and in FWHM (two-way student t-test, n ≥ 21, *p = 0.0001). 
  





Figure 17. Developmental toxicity assay of cardiac organoids in response to treatment with 
Doxycycline (Category D). In all assays, cardiac organoids failed to differentiate at 100 µM 
treatment, and toxicity was also observed in contraction velocity (two-way student t-test, n ≥ 7, *p 
= 0.0036), beat rate (two-way student t-test, n ≥ 7, *p ≤ 0.0067), beat duration (two-way student t-
test, n ≥ 7, *p ≤ 0.0001),  and height (two-way student t-test, n = 8, *p ≤ 0.0061 relative to controls) 
and in FWHM (two-way student t-test, n ≥ 21, *p = 0.0001). 
 
  





Figure 18. Developmental toxicity assay of cardiac organoids in response to treatment with 
Lithium carbonate (Category D). No significant toxicity effects were seen in any contraction 
function. However, moderate toxicity was seen in all concentrations for the area ratio (ANOVA, 
n ≥ 26, *p ≤ 0.0001) and in FWHM (ANOVA, n ≥ 20, *p ≤ 0.0001) relative to the controls. 
  





Figure 19. Developmental toxicity assay of cardiac organoids in response to treatment with 
Phenytoin (Category D). Phenytoin showed no contractile functions at 100 µM concentration, 
with moderate effects at 1 µM on beat rate (two-way student t-test, n ≥ 11, *p = 0.0165) and beat 
duration (two-way student t-test, n ≥ 11, *p = 0.0101). Organoids were also smaller in area ratio 
at 10 µM treatment (two-way student t-test, n = 28, *p = 0.0006) and smaller at all concentrations 









Figure 20. Developmental toxicity assay of cardiac organoids in response to treatment with 
Tretinoin (Category D). Cardiac tissue failed to develop at 10 µM concentrations with no 
contraction functions. Contraction velocity was lower at 0.1µM (two-way student t-test, n ≥ 7, *p 
= 0.0274), whereas beat rate was faster at 0.1µM and 1 µM (ANOVA, n ≥ 7, *p = 0.0001). Beat 
duration was significantly lower at 1 µM (two-way student t-test, n ≥ 7, *p ≤ 0.0001) as well. Low 
concentration of 0.1 µM also showed toxic effects on area ratio (two-way student t-test, n ≥ 12, *p 
≤ 0.0112), height (two-way student t-test, n ≥ 8, *p = 0.0004), and FWHM (two-way student t-
test, n ≥ 12, *p ≤ 0.0001). 
 
  





Figure 21. Developmental toxicity assay of cardiac organoids in response to treatment with 
Isotretinoin (Category X). Cardiac tissue failed to develop at 1 µM and 10 µM concentrations 
with no contraction functions. Low concentration of 1 µM resulted in faster beat rate (two-way 
student t-test, n ≥ 13, *p ≤ 0.0007) and smaller area ratio (two-way student t-test, n ≥ 31, *p ≤ 
0.0001). However, high concentrations produced organoids that were significantly taller in height 
(ANOVA, n ≥ 9, *p ≤ 0.0001) and larger in FWHM (ANOVA, n ≥ 12, *p ≤ 0.0001). 
  





Figure 22. Cardiac looping scored as a cardiac developmental toxicity evaluation in the 
zebrafish whole embryo culture assay (zWEC). Zebrafish embryo heart structures were scored 
based on loop structure, where (a) D-looped heart structures are the normal expected structure. No 
significant drug effect from (b) doxylamine succinate exposure, and a very mild toxicity level from 
high dosage exposure of (c) thalidomide. A sample size of n>40 embryos were analyzed for these 
treatment groups.  
 
  





Figure 23. Zebrafish whole embryo culture (zWEC) assay of cardiac looping for seven drug 
compounds. (a) Category B amoxicillin and (b) Category C rifampicin produced mild 
developmental toxic effect. (c-f) Category D drugs displayed developmental toxic effects ranging 
from moderate (lithum carbonate, phenytoin, and doxycycline) to severe (tretinoin). (g) Category 
X isotretnoin produced severe developmental toxic effects at all concentrations. (h) Morphological 
scoring was performed on heart structures of developing zebrafish embryos based on either normal 
(D-loop), reverse (L-loop), no loop, or no score where the heart did not express GFP and/or fall 
into the previous three categories. A sample size of n>19 embryos was used for all treatment 
groups.  








Drug Medicinal Use Pregnancy 
Category  
Concentrations Tested 
Doxylamine Succinate Antihistamine, sleeping aid A 1 μM, 10 μM, 100 μM 
Amoxicillin Antibiotic (strep, middle ear 
infections etc.) 
B 1 μM, 10 μM, 100 μM 
Rifampicin Antibiotic (TB, leprosy etc.) C 1 μM, 10 μM, 100 μM 
Lithium Carbonate Bipolar antidepressant D 1 μM, 10 μM, 100 μM 
Phenytoin Anticonvulsant D 1 μM, 10 μM, 100 μM 
Doxycycline Antibiotic D 1 μM, 10 μM, 100 μM 
All-trans-RA 
(Tretinoin) 
Acne treatment D 0.1 μM, 1 μM, 10 μM 
13-cis-RA 
(Isotretinoin) 
Acne treatment X 0.1 μM, 1 μM, 10 μM 
Thalidomide Myeloma, Inflammation X 1 μM, 10 μM, 100 μM 
 




5. Chapter 5:  Single cell characterization of cardiac organoids using 
next generation sequencing technologies       
 
Overview 
This Chapter discusses the characterization of cardiac organoids at single cell genomic resolution. 
The goal of this study was to analyze the single cell genomic profiles that compose cardiac 
organoids using single cell RNA sequencing (scRNAseq). We performed scRNAseq and 
bioinformatics data processing to identify cell populations obtained from the cardiac organoid 
arrays. Since scRNAseq requires high quality cells at high viability, preliminary studies were first 
performed to assess cell viability after dissociation and flow cytometry analysis. scRNAseq was 
proposed because the organoid field is currently taking advantage of this technology to 
characterize cell types generated in stem cell-derived organoids. This allows us to study the 
organoid function based in individual cell contributions as well as characterize the extent to how 
organoids recapitulate in vivo tissue.  
 
5.1 Motivation 
Mammalian heart development is governed by complex signal transduction pathways that drive 
the transformation of a linear heart tube into a four-chambered heart106. In addition, these processes 
involve different cell types, including cardiomyocytes, endocardial cells, epicardial cells, and 
smooth muscle cells that synergistically perform specific functions essential to heart 
development107. Use of next generation sequencing technologies has been growing at an 
exponential rate over recent years because of its powerful ability for high throughput study of the 
genomic profiles and functions of individual cells108, which gives important insight on cell 




populations within a tissue, especially for stem cell-derived tissue models. More specifically, 
scRNAseq has been applied to identify cell diversity within complex tissues109, including brain 
organoids110–114, gut organoids115,116, as well as in murine and human myocardium106,107,117,118. 
 
From the IHC characterization, the region-specific staining patterns indicate two primary cell types 
within the cardiac organoids. However, this does not illustrate the potential diversity of these types, 
or the rare and unknown cell subtypes that may also exist. Flow cytometry (FACS) was first used 
to provide preliminary data to approximate cell viability as well as the approximate the cell 
population fractions that we can expect to see with scRNAseq. FACS, however, is limited to only 
a small number of protein markers that can be tagged, which only provides a simple quantification 
of the fraction of cells expressing those specific markers. This cannot output the in-depth genomic 
profiles that scRNAseq can provide, which is a high-resolution profile of each cell that will allow 
the segregation of cells based on common expression patterns of all sequenced genes. scRNAseq 
will supply more definitive classification of cells that compose the organoids. This will provide 
insight on the embryonic profile of the cardiac organoids so that their respective stages can be 
cross-referenced with the corresponding stages in mammalian heart development.  
 
5.2 Cardiac organoid characterization 
5.2.1 Cardiac organoid dissociation 
The cardiac organoids generated using the method described in Chapter 2 results in tissues that are 
adhered to TCPS. As such, the organoids require dissociation and singularization for scRNAseq 
analysis. The organoids were generated using 600 um patterns and sacrificed on Day 20. Organoids 
were then isolated by physical scraping off excess residual cells and tissue that can potentially 




skew the single cell profiling of the organoids. The organoids were then dissociated for 10 minutes 
using 0.25% Trypsin and quenched with FBS supplemented media.  
 
5.2.2 Characterization using flow cytometry 
After pelleting and resuspension, the cells were strained to further singularize cell clusters. 
Singularized cells were prepared for FACS analysis by fixing with 4% paraformaldehyde and 
stained with cardiac troponin T (cTnT) antibody (cardiac marker) and vimentin antibody (stromal 
marker). FACS analysis showed that approximately 80% of cells are positive for vimentin and 
50% of cells are positive for cTnT. However, repeats of these studies showed inconsistency and 
high variability with the marker distributions.  
 
5.2.3 Assessment of cell viability of singularized organoids 
Cell viability was carefully addressed, since the quality of cells can have significant impact on the 
cellular expression profiles in scRNAseq. In addition, all genomics sample processing was to be 
performed at the Cornell Biotechnology Resource Center (BRC) (Figure 24), which requires 
approximately 1.5 hours of transportation time. After consultation, the recommended cell viability 
should be at least 50%. The viability of the organoids was assessed immediately after straining 
and at 30 minute intervals over a 2-hour time period using automated cell counting. During this 2 
hour period, the cells were stored on ice and supplemented with 1% HEPES buffer, as it is often 
recommended to promote cell survival over long periods of time. After 2 hours, the cell viability 
was negligibly affected, remaining at approximately 80% viable cells. This preliminary study 
showed that the dissociation and singularization did not significantly impact cell integrity and was 
sufficient for sample processing at the Cornell BRC. 
 
5.3 Single cell RNA sequencing of cardiac organoids  




5.3.1 scRNAseq data acquisition and pre-processing 
Organoids from 600 um patterns were used for initial preliminary scRNAseq processing. Cells 
were dissociated and singularized following the procedure outlined in the previous section 
(Chapter section 5.2). Library preparation, sequencing, and alignment of reads was performed 
following a standard 10X Genomics pipeline (Figure 24a). Libraries were prepared from the 10X 
Genomics Chromium, followed by a sequencing run of 75 base pairs (Illumina NextSeq500). Raw 
reads were processed using the CellRanger analysis pipelines to demultiplex, align, and filter gene 
expression reads for downstream analysis. From this initial experiment, the output  data consisted 
of 4805 cells. The read count of these cells ranged from 500 to 194,572 counts, with the number 
of detected genes ranging from 43 to 11,308 features.  
 
Preprocessing analysis was carried out using Partek Flow, courtesy of a shared license provided 
by the SUNY Upstate Medical University Genomics Core. Single cell RNA sequencing data 
contains noise as well as reads from low quality cells as a result from sample preparation 
procedures required. Preprocessing of data consists of various steps to normalize and filter cells 
and genes to include only high-quality cells that can provide optimal biological information. The 
single cell data was normalized using default recommended parameters (counts per million, Add 
1, Log2). Single cell QA/QC was then performed to filter out low quality cells. Cell quality was 
assessed based on violin plot distributions of read counts (Figure 24b), detected features (Figure 
24c), and percentage of mitochondrial counts (Figure 24d). From the distribution plots, cells were 
downscaled to ~3000 cells, which include those with read counts greater than 2800, detected genes 
greater than 1300, and mitochondrial counts of less than 30%.  
 




The primary goal of this chapter is to identify cell populations within the total pool of cells. We 
based our study criteria to only include genes that are differentially expressed within the entire 
pool of cells. Therefore, we chose to apply a statistics-based filter based on variance of the detected 
genes, which will identify differentially expressed genes. As the cell populations within the cardiac 
organoids are unknown, we assumed that genes with high variance would distinguish one cell 
population from another. The feature filter was applied to only include the top 1000 genes with 
the highest variance. This filter removes most genes from downstream analysis, but particularly 
genes that have comparable expression profiles between all cells. These commonly expressed 
genes are often involved in metabolic and general cell functions, which do not provide information 
on the distinct functions of a specific cell type.  
 
5.3.2 Downstream processing of scRNAseq data 
The previous section 5.3.1 outlines necessary processing steps to clean and optimize raw 
scRNAseq data output for downstream applications to be performed on Partek Flow. These 
downstream processes include clustering, differential expression, pathway, and trajectory analyses 
to classify cells within the population, as well as gain higher-level biological insight exhibited by 
cardiac organoids. Principal component analysis was first applied to reduce the data 
dimensionality. Graph-based clustering was then applied to segregate cells within the population 
into specific groups of which cells within that group exhibit similar expression profiles. Using the 
600 µm cardiac organoids, the graph-based clustering method identified approximately ten cell 
populations within the sample. These clusters were then visualized with T-distributed stochastic 
neighbor embedding (t-SNE) (Figure 24e), where each dot corresponds to an individual cell 
belonging to an assigned cluster based on the specified color. Cells can also be visualized using 




trajectory analysis (Figure 24f), which aligns each cell along a trajectory branch that corresponds 
to a cell state. Cells from the organoids aligned along a three-branch trajectory, meaning that the 
cells are primarily in three different states. We examined the differential gene expression profiles 
of cell clusters along each branch and inferred that the three primary states are cardiac, endodermal, 
and stromal cell lineages.  
 
5.3.3 Classifying cardiac organoid cell type composition 
We first confirmed the presence of the two known cell types, both cardiomyocytes and smooth 
muscle-like or stromal cells, which were identified from immunofluorescence staining 
characterization used in previous chapters. Using the t-SNE plot, cells were highlighted based on 
their expression of known specific markers of the cells of interest. MYH6, ACTN2, and MYBPC3 
were used as cardiac markers and the expression of these genes was concentrated in clusters 1 and 
7 (Figure 25a, b). Next, we profiled the expression of TAGLN2 and ACTA2, which are smooth 
muscle markers that were used in previous immunofluorescence characterization (Figure 25c, d). 
These genes exhibited scattered distribution across multiple cell clusters. Violin plot expression 
profiles of TAGLN2 across all cells illustrated the highest expression in all clusters except for 1 
and 7, these of which were determined as the cardiomyocyte populations. This verified that the 
organoids were composed of cardiomyocytes and stromal-like cells, as predicted. 
 
The differentially expressed genes were then visualized using heat maps and hierarchical 
clustering of the genes to compare gene expression profiles across clusters (Figure 26). We 
generated a gene heat map and performed hierarchical clustering on a reduced list of the top 100 
genes with the highest variance. To further classify the cell populations, we evaluated the genes 




with the highest scaled expression based on the standardized z-score, indicated by the red coloring 
on the heat map, as these genes are likely the features that distinguish one cell cluster from another. 
For cardiomyocyte cell populations 1 and 7, MYL3 is downregulated in cluster 7 and upregulated 
in cluster 1. This suggests that cluster 1 cells are ventricular-like cardiomyocytes, as MYL3 is a 
specific marker for cardiac ventricular muscle119. Therefore cluster 7 are likely atrial-like 
cardiomyocytes, or immature fetal striated muscle cells. This trend can also be seen in the 
trajectory plot, where cluster 7 cells are not as concentrated or as far along the branch as cluster 1.   
 
Genes that were upregulated in cluster 2 are involved in tissue morphogenesis and growth (VCAN, 
PLAC9, IGFBP2). Additionally, cardiac specific genes were also upregulated, relative to the 
remaining non-cardiomyocyte clusters. Therefore, we inferred that cluster 2 is a population of 
progenitor cells with the potential for cardiac specificity.  Clusters 3, 5, and 8 showed similar 
expression profiles, particularly for genes directly involved in collagen production (COL1A2, 
COL3A1, COL1A1). This corresponds to stromal cells, including fibroblasts and smooth muscle. 
From the heat map, ACTA2, TAGLN, and MYL9 were differentially expressed in cluster 5 only, 
suggesting that these cells are likely smooth muscle cells, while clusters 3 and 8 are subtypes of 
stromal cells.  
 
Interestingly, we classified multiple clusters of cells of endodermal lineage. This is attributed to 
the differentiation protocol, which specifically targets Wnt signaling that also plays a role in 
regulating endoderm patterning120,121. Additionally, liver development is facilitated through 
synergistic paracrine signaling with the heart122, which can explain the endodermal specification 
in the cardiac organoids. Clusters 4 and 6 expressed upregulated genes related to endodermal and 




epithelial cell lineages (EPCAM), but also genes related to immune cell inflammatory response 
(ALB, CD24, and FGG). Lastly clusters 9 and 10 had the fewest distinguishable gene expression 
patterns based on the heat map, likely because these populations had the fewest cells. However, 
from the trajectory plot, these clusters were scattered along the same branch state as clusters 4 and 
6, implying a relation between these four clusters.  
 
5.4 Single-cell genomics characterization of cardiac organoid lineage specification directed 
by geometry size 
To study how geometric confinement affected the cell fate choice of cardiac organoids, we profiled 
the gene expression of organoids generated from 200 μm, 600 μm, and 1000 μm diameter circular 
patterns with single cell RNA sequencing. Ten unique cell populations were identified (Figure 27) 
using integrated datasets of these three shapes (63,175 cells). Cell populations were determined 
using a differential gene expression filter of the 1000 genes exhibiting the highest variance, 
followed by principal component analysis and graph-based clustering. Trajectory analysis was 
then performed, which classified the cells into the three primary cell lineages that cardiac 
organoids exhibit (cardiac, stromal, or endodermal) (Figure 28a). Individual cell clusters from 
these lineages were classified by identifying the presence of and assessing the expression gradients 
of cell specific markers that are unique to these three lineages (Figure 28c, Figure 29). Three cell 
types within the cardiac lineage branch were classified as two populations of cardiomyocytes 
(atrial-like and ventricular like) and cardiac-mesodermal progenitor cells. Cells along the 
endoderm branch were classified as hepatocyte-like cells, hepatoblast-like cells, hepatic epithelial 
cells, as well as endoderm and mesoendoderm progenitor cells. Lastly, cells along the stromal 
branch of the trajectory were composed of fibroblast and smooth muscle-like cells, but very few 




expressions of vascular endothelium (KDR, FLT1, ICAM, PECAM, CDH5). Meanwhile, these 
stromal cells showed affinity to produce signaling factors promoting the hepatic epithelium 
development (HGF). Expression pattern of transcription factors (TBX) and signaling molecules 
related to WNT and BMP signaling cascade were primarily sequestered towards either cardiac or 
hepatic cell lineages. For instance, the HHEX activation seen in endodermal cells is likely 
facilitated by the high BMP signaling from cardiac cells123. This suggested that the organoids 




Two major cell clusters containing ~68% cells are cardiomyocytes and hepatic epithelium. More 
importantly, each of these two clusters were further divided into two sub-clusters based on the 
pattern sizes (Figure 30). Comparing 200-µm pattern with 600-µm and 1000-µm patterns, the 
cardiomyocyte population was clearly separated between pattern sizes (blue v.s. green) due to the 
different expression level of cardiac-specific genes. This was also observed on the hepatic 
epithelial cell population (red v.s. purple). The organoids generated from the 200 µm patterns 
contained the cardiomyocytes (blue) and hepatic epithelial cells (purple) at the early differentiation 
stages, meanwhile they also had larger populations of progenitor cells (cardiac mesoderm, hepatic 
endoderm and mesoendoderm-like cells), in comparison to the 600-µm and 1000-µm organoids. 
This indicated that small organoids were delayed in the differentiation of organ-specific cell types, 
and also retained large population of premature cell types. Mid-sized organoids from 600 µm 
patterns had the largest fraction of late differentiated cardiomyocytes and smooth muscle-like cells, 
and fewer progenitor cells and endodermal cells, indicating a high-efficiency in muscle 




specification. In contrast, large organoids from 1000 µm patterns, promoted greater differentiation 
into endodermal and hepatic cell populations. 
 
Hierarchical clustering and gene ontology (GO) pathway analysis were performed to assess 
specific biological processes between cell types (Figure 31).  GO analysis of the cardiomyocyte 
populations showed high specificity for heart-related functions, such as regulation of heart 
contractions and cardiac muscle tissue morphogenesis. Pathways related to the progenitor cells 
indicated less specific cell functions, indicating that these cells are not yet organ-specific and are 
likely premature. Lastly, pathways corresponding to endodermal cells were related to liver, 
metabolic and endocrine processes. By comparing the sizes with genes specific to each of the three 
primary cell lineages (cardiac, endodermal, and stromal) (Figure 32), genes related to cardiac 
development were expressed to a higher degree in the 600 µm organoids. In contrast, smaller 200 
µm patterns produced the organoids with high expression of the genes related to stromal cells, 
while larger 1000 µm patterns produced the organoids with high expression of the genes related 
to hepatic development. Although our protocol was targeted to the cardiac muscle differentiation, 
these results indicated that the influence of geometric size on the co-emergent cell lineage 
transition from stromal cells with small organoids, to cardiac mesoderm with mid-size organoids, 
and to hepatic endoderm with large organoids. 
 
5.5 Conclusions and discussion 
In this study, we profiled the cellular diversity of the cardiac organoids using scRNAseq and 
bioinformatics analysis. Cells that compose cardiac organoids are a result of three primary cell 
lineages: cardiac, stromal, and endodermal cells. In addition, we profiled the cellular diversity 




resulting from organoids generated in different circular sizes and observed lineage specification 
that is driven by the geometric size. We found that cardiac lineage specification was optimized in 
mid-sized (600 µm diameter) organoids, which supports previous structure and function 
characterization of size effects on organoid production discussed in Chapter 3. Small organoids 
(200 µm diameter) promoted differentiation into progenitor-like cells, whereas large organoids 
(1000 µm diameter) promoted a high percentage of endodermal cell differentiation. 
 
The attributes unique to the 200 µm organoids suggests that small confinement directs cells to 
differentiate into progenitor-like cells that are less specific and do not have gene expression 
patterns indicative of terminal cell types. This shape also produced organoids composed of 
cardiomyocytes that differ from the targeted ventricular cardiomyocytes, suggesting that very 
small confinement size can influence the cardiomyocyte differentiation trajectory. These attributes 
can also be associated with the inability of cardiac organoids to consistently and reliably 
differentiate in this size, as these organoids display the highest variabilities in 3D structure, 
contraction functions and differentiation efficiency. Mid-sized 600 µm organoids produced the 
largest fraction of ventricular-like cardiomyocytes, indicating an optimal size for cardiomyocyte 
differentiation to compose the organoids. This data supports the analysis of the structural 
morphology of cardiac organoids relative to size, where 600 µm organoids exhibited the largest 
3D architecture based on imaging analysis and staining patterns of cardiomyocyte specific 
markers. From the t-SNE plots, 1000 µm organoids also displayed a comparable density of 
ventricular cardiomyocytes to 600 µm organoids, but at a lower percentage due to the strong 
promotion of endodermal cells. Comparable cardiomyocyte differentiation can be correlated with 
the structural analysis of the organoids, where organoid sizes greater than 600 µm did not have 




enhanced 3D cardiac structure, relative to 600 µm organoids, as the size increased. This suggested 
that cardiomyocyte differentiation reaches a limiting point that is controlled by geometry.  
 
Since organoids models are hypothesized to model organ development and functions, utilizing 
scRNA-seq is a powerful tool to understand the degree of developmental recapitulation114,115,124. 
In cardiac development, scRNA-seq has facilitated the identification and mapping of rare cell types 
that can uncover biological mechanisms involved in disease125. Based scRNA-seq of the human 
fetal heart117,118, the cardiac organoids are able to recapitulate multiple major cell types that were 
seen in human embryos, including cardiomyocytes smooth muscle cells and cardiac fibroblasts, 
but lack of epicardial development and vasculogenesis. Interestingly, though our differentiation 
protocol primarily focuses on the cardiac lineage induction, the formation of cardiac organoids 
resembles the co-emergent cell induction into both cardiac and hepatic lineages, which was also 
observed from other organoid models126. Due to the close proximity in embryo development, 
paracrine signaling from the heart facilitates the specification of hepatic epithelium from endoderm 
layer, which is the first step of liver development122,127. Our results not only indicated that parallel 
multi-lineage specification of the heart-liver synergy that occurred in our cardiac organoid model, 
but also demonstrated that external biophysical cues can modulate these co-emergent 









Figure 24. Single-cell RNA sequencing and bioinformatics workflow. (a) Single-cell RNA 
sequencing pipeline using 10X Genomics from sample preparation to data output using 
CellRanger. Single cell data is plotted as a series of violin plots for quality control. Quality control 
of output data involves filtering of (b) read counts, (c) detected features, and (d) percent 
mitochondrial counts. Single cell data is then clustered into cell types based on PCA 
dimensionality reduction and visualized using (e) t-SNE and (f) trajectory trees to identify cell 
types.   





Figure 25. Cell-specific gene identification of cardiomyocytes and stromal cells. (a) 
Cardiomyocytes were identified by locating the cell cluster expressing cardiomyocyte markers 
ACTN2, MYBPC3, and MYH6. (b) MYH6 expression showed to be highly specific to clusters 1 
and 7, identifying two sub-populations of cardiomyocytes. (c) Stromal cell markers TAGLN2 
and ACTA2 confirmed the presence of stromal cells and (d) displayed scattered expression 
across multiple cell clusters, except in the cardiomyocyte populations.   





Figure 26. Heat map of top one hundred differentially expressed genes for cell cluster 
classification. Genes were filtered to only include the top 100 genes with the highest variance. 
These differentially expressed genes were used to approximate the classification of the cell type 
composing each cluster.  





Figure 27. Integrated t-SNE plot of classified cell clusters composing 200 µm, 600 µm, and 
1000 µm cardiac organoids. t-SNE plot of cells (>63,000) colored by cell type. Cells were 
clustered based on PCA and graph-based clustering.   





Figure 28. Classification of cell clusters using trajectory analysis and identification of cell-
specific genes. (a) Trajectory analysis of cardiac organoids of different sizes fall in three primary 
cell lineage branches: cardiac, stromal, and endodermal. (b) Lineage specific markers were 
mapped to locate and further classify the cell populations illustrated within the t-SNE.  
  





Figure 29. The t-SNE expression maps for vasculogenic, cardiogenic, and hepatogenic 
signaling factors in the cardiac organoids. Cardiac organoids showed low indication of 
vasculogenesis, but high indication of paracrine signaling between mesodermal cardiac lineages 
and endodermal hepatic lineages 
  





Figure 30. Fractional composition of cell types in small, mid-size, and large organoids. 
Cardiac organoids of different sizes drive differential cell specification. Small organoids (200 
micron) had higher fractional compositions of early cell types and progenitor cells. Mid-size 
organoids (600 micron) had the highest fraction of cardiomyocytes and smooth muscle cells. 
Large organoids (1000 micron) had the highest fraction of endodermal cells.  
  





Figure 31. Heat map and pathway analysis of cardiac organoid cell types. Gene ontology 
pathway analysis was performed using a range of 10-20 genes for each major cell cluster.   





Figure 32. Cardiac, stromal, and endodermal gene expression patterns relative to cardiac 
organoid size. Fold change expression patterns were plotted to compare gene expression across 
the three pattern sizes. Genes were selected based on specificity to cardiac, endodermal, and 
stromal cell lineages. 
 




6. Chapter 6: Quantitative characterization of drug-induced cardiac 
arrhythmias using nonlinear computational tools 
 
Overview 
In this Chapter, we describe computational workflow based on nonlinear phase space 
reconstruction (PSR) to depict the deterministic dynamics of chaotic nature in the contractile 
motions of cardiac tissues before and after drug administration. Through PSR, one-dimensional 
(1D), or linear time-series signals can be mathematically modeled in high-dimensional space to 
derive parameters for signal characterization. The new algorithm provided by a collaborative effort 
with Professor Sabir Jaquir (Université Paris-Sud, Université Paris-Saclay, Neuro-PSI) presented 
an analytical tool to quantitatively classify the arrhythmic contractile motions of hiPSC-CMs for 
more precise drug cardiotoxicity screening. By integrating hiPSC technology, optical flow 
computation and this new analytical tool, we envisage to measure abnormalities in heart 
contraction related to drug-induced arrhythmia in an automated, high-throughput and quantifiable 
manner128,129.  
 
6.1  Background and rationale 
Over recent years, there has been increasing interest of using nonlinear analysis to study human 
biological signals, since maintenance of stability in physiological functions involves 
interconnected feedback loops between biological systems. Such high degrees of interdependency 
require in-depth investigation on the level of complexity and variability of the biological systems 
for better understanding of their regulatory mechanisms. Cardiac rhythm has gained widespread 
attention, because it is known to exhibit considerable signal complexity in healthy individuals from 




normal day-to-day activities. Additionally, cardiovascular diseases are often associated with 
irregularities in cardiac contraction, frequency and rhythm130.  
 
Cardiac physiology is traditionally quantified using linear analytical approaches that analyze 
cardiac signals (e.g. electrocardiograms (ECG)) in the time and frequency domains131–133, 
including optical flow contractile motion tracking (Chapter 2). However, current optical flow 
analysis suffers from simplified conventional analytical tools of dominant frequency analysis132 
and amplitude analysis133, providing time-series waveforms with measurement of beat rate, 
contraction velocity, relaxation velocity and beat duration. Such analysis cannot faithfully predict 
the complex biological behaviors and physiological signals to determine and classify the level of 
arrhythmic contraction response to drug interference quantitatively, statistically and 
systematically. 
 
There is increasing evidence suggesting that nonlinear analysis can be used in conjunction with 
standard diagnostic methods to quantify individual physiological states134. Differences in the 
nonlinear indices can be monitored between healthy and sick individuals, including cases of 
emotional stress, environmental changes, or genetic cardiomyopathies. Methods from chaos theory 
and nonlinear dynamics give us the opportunity to study these complex biological signals, 
including entropy135, complexity indexes136 and dimensional analysis137. Specifically, the phase 
space consists of a set of typical trajectories of the system, in which each point corresponds to one 
system state. The nonlinear properties, therefore, are a representation of the degree of regularity 
and complexity of a signal. Analyzing the dynamic properties of a waveform represents a useful 




tool for identifying the number of independent variables necessary for generating a corresponding 
process or state. 
 
Nonlinear analysis based on PSR has previously been applied to analyze electrophysiological 
signals to identify arrhythmia both in vitro and in vivo. Electrical field potentials from nrCMs 
recorded by MEA were subjected to PSR to compute the parameters that quantified the unique 
dynamics of normal versus arrhythmic signals138,139. PSR was also used to analyze heart rate 
intervals of electrocardiograms (ECGs)140,141 and magnetic resonance image (MRI) data142 
acquired from patients with different heart pathologies. The parameters computed from PSR, such 
as embedding and correlation dimensions, varied considerably between groups with different heart 
diseases, further reiterating the ability of PSR to quantitatively measure the dynamics of cardiac 
signals140. 
 
Despite the application of nonlinear analysis to the clinically acquired signals (e.g. ECG), such 
analysis has not been widely applied for in vitro cardiac model systems. With the rising interest in 
human induced pluripotent stem cell (hiPSC) derived cardiomyocytes (hiPSC-CMs), it is of utmost 
importance that we are able to characterize their contractile functions and heartbeat rhythm in a 
more precise and comprehensive manner. However, current approaches to characterize the 
contractile physiology of hiPSC-CMs still heavily depend on amplitude133 and frequency132 
analyses of physical and electrophysiological data. These conventional analytical tools only draw 
simplified readouts from complex biological signals. This poses the challenge of gaining 
informative analytical outcomes from hiPSC-CMs to assess comparability with native tissue and 
responsiveness to external stress143. In addition, hiPSC-CMs exhibit higher variability144,145 in their 




contractile behaviors than the adult human heart even under normal conditions, which further 
emphasizes the need to integrate novel analytical methods to in vitro cardiac model systems. 
 
To address this limitation, we took advantage of mathematical chaos theory to identify the 
nonlinear dynamic characteristics of hiPSC-CMs contractile motions recorded using optical flow 
and block-matching methods. More specifically, a phase space reconstruction (PSR) method141,146–
148 was used to convert our biological dynamic system into a phase space consisting of a set of 
typical trajectories, in which each point is corresponding to a system state.  
 
6.2  Materials and methods 
6.2.1  hiPSC-CM differentiation, video microscopy and motion tracking 
hiPSCs were first seeded onto Matrigel-coated -6-well tissue culture plates at 25,000 cells/cm2 and 
cardiac differentiation was performed via modulation of the canonical Wnt signaling pathway64 
outlined in Chapter 2.3.3. Video recordings of the beating hiPSC-CMs were taken at standard 
physiological conditions and at 100 fps, followed by motion tracking analysis, as discussed in 
Chapter 2.4.1.  
 
6.2.3  Calcium flux imaging and analysis of GCaMP6f hiPSC-CMs 
For calcium flux imaging, GCaMP6f hiPSC-CMs were generated from GCaMP6f hiPSC line with 
the same differentiation protocol. GCaMP6f hiPSC-CMs can activate the fluorescence from green 
fluorescent protein as an indication of the increased cytoplasmic calcium levels that occur during 
hiPSC-CM contraction. The calcium flux images were recorded at 30 frames per second for 10 
seconds and exported as single frame images. The fluctuations in fluorescent intensity were plotted 




by the Z-axis profile in ImageJ, corrected the fluorescent bleaching decay by in-house MATLAB 
script, and analyzed by phase space reconstruction algorithm. For drug response studies, we 
recorded the baseline contraction in both brightfield transmitting light for motion analysis and the 
fluorescence emitted by the GCaMP protein for calcium flux analysis. Each drug was 
incrementally added to the culture media to achieve a range of treatment concentrations and videos 
were recorded immediately after each addition.  
 
6.3  Reconstruction of time-series contraction waveforms 
The workflow of our analytical approach started with video recording of purified beating hiPSC-
CMs, plated in standard 2D culture, using a bright-field or phase contrast microscope. The 
recorded videos were subjected to motion tracking analysis to generate motion vectors that 
measure the motion velocity and beat frequency. Motion tracking data was then decomposed using 
PSR and from this, a set of dimensional parameters can be generated to reflect the dynamics of the 
motions regarding to regularity and complexity (Figure 33). We then selected two motion 
waveforms generated from video analysis using motion tracking software, one represented regular 
cardiac contraction, while the other represented irregular (complex) cardiac contraction. Then, we 
reconstructed these two motion waveforms into phase spaces, respectively (Figure 34a-d). For 
each time lag, we can reconstruct a corresponding phase space through the time lagged method, 
and the PSR evolved with the increase of time lag for each motion waveform. We selected the 
PSR with τ = 15 for both motion waveforms and showed that the PSR for complex contractile 
motion appeared to have higher degrees of convolution and eccentricity in comparison to the PSR 
for regular motion (Figure 34a, c). This verified that distinct cardiac motion waveforms can be 
represented in the phase spaces that were spatially distinguishable from one another. 





Initial output parameters from the PSRs include the embedding (m), regularity (𝝆 = 𝝉
𝒎
), and 
fractal (d) dimensions (Calculations supplied in Appendix A). The embedding and regularity 
dimensions measure the overall rhythmic regularity of the gross peaks within a waveform, while 
fractal dimension quantifies the complexity, which is a measure of the aberrations within the 
system (Figure 34e-h). We compared the embedding dimension for the single waveforms of both 
regular and complex motion by averaging all values over the entire variance of time lag. The 
average embedding dimension for complex cardiac contractile motion was significantly greater 
than the average for regular motion (Figure 34e), which translated to lower regularity dimensions 
over all values of time lags (Figure 34f). We can utilize embedding and regularity dimensions to 
measure and compare the motion regularity between two distinct waveforms. In contrast, the 
fractal dimension quantifies the complexity of the waveforms. We found that the fractal dimension 
was greater for complex contractile motion, which was consistent for all the time lags (Figure 34g, 
h), inferring that larger values of fractal dimension reflect greater complexity of the time series. 
  
6.4  Noise sensitivity of phase space reconstruction 
To further characterize the different dimension parameters responding to the system aberrations, 
we then applied random background noise ranging from 0-50% of the mean contraction velocity 
to a signal. The addition of background noise generated random deviations within the original 
motion waveforms, allowing us to study the influence of noise on the regularity and complexity 
of the cardiac contractile motion. By visual inspection, the increasing increments of noise 
introduced coarser aberrations within the signal, but the overall rhythmic regularity remained 
conserved, as indicated by the identical gross contraction peaks (Figure 35a). The addition of 




random noise, therefore, didn’t influence the regularity of the motion, since the overall cardiac 
beating rhythm wasn’t altered. Thus, the embedding and regularity dimensions remained constant 
for all quantities of random noise (Figure 35b, c). Since noise creates variations in the signal, we 
found that increasing levels of noise on the original signal led to an increase of fractal dimensions 
(Figure 35d, e), which suggested that the fractal dimension is sensitive to noise and secondary 
variations in the signal. Therefore, we can quantify the secondary aberrations as the system 
complexity for the cardiac contractile motion.  
  
6.5  PSR sensitivity to drug response 
6.5.1  hiPSC-CM drug treatment  
To investigate the ability of PSR method for quantifying the drug-induced cardiac motion 
abnormalities, indicative of cardiac arrhythmia, we treated hiPSC-CMs with four drugs 
(propranolol, E4031, metoprolol, and isoproterenol) known to influence cardiac beat rhythm and 
motion. For each drug, we first recorded the videos of baseline control, then immediately treated 
the hiPSC-CMs at two incremental drug concentrations and generated corresponding motion 
waveforms using motion tracking software. By performing motion tracking analysis on the beating 
videos, we analyzed the beat rate and maximum contractile velocity of the hiPSC-CMs treated 
with different drug concentrations versus the baseline control. The beat rate was defined as beats 
per minute based on frequency analysis of the motion waveforms, while the maximum contractile 
velocity was defined as the average contraction peak magnitude based on amplitude analysis of 
the motion waveforms. Next, we performed the PSR analysis on the motion waveforms and 
computed the corresponding embedding, regularity and fractal dimensions. 
 




6.5.2  Propranolol 
Propranolol, a beta blocker used to treat high blood pressure and post-myocardial infarction, has 
been reported to induce arrhythmias by causing bradycardia. We observed abrupt arrhythmic 
motion as a result of propranolol treatment. The resulting PSR analyses showed that, with respect 
to propranolol (Figure 36), the average embedding dimension increased with increasing 
propranolol concentration, which translated to a reduction of regularity dimension with higher 
concentrations of propranolol. However, fractal dimensions have no significant difference between 
baseline and two concentrations of propranolol, indicating propranolol treatment did not 
dramatically influence the complexity of cardiac contractile motions. 
 
6.5.3  E4031 
E4031 is a hERG potassium ion channel blocker that prolongs the QT interval and result in lethal 
arrhythmias. Treatment with E4031 (Figure 37), displayed increased embedding dimension and 
decreased regularity dimension in response to the drug, which implied that E4031 induced 
arrhythmic contractile motions. Furthermore, E4031 treatment induced an increase of fractal 
dimension, especially for high dosage of the drug. This suggested that E4031 not only induced 
arrhythmic motions, but also induced contractile aberrations to the hiPSC-CMs. 
 
6.5.4  Metoprolol 
Metoprolol is a beta blocker and is used to treat conditions that cause abnormally fast heart rate. 
Metoprolol-induced arrhythmias (bradycardia) can occur at excessive dosages. Application of 
metoprolol up to 40 µM resulted in no significant changes of contraction motion. Although 
metoprolol falls within the same drug category as propranolol, it is a milder and less potent beta-




adrenoceptor antagonist with lower effect of attenuating beat rate than propranolol149,150. Based on 
the PSR analysis, there was no significant difference in either the embedding, regularity, or fractal 
dimensions for all concentrations of the drug (Figure 38). This indicated that metoprolol does not 
induce arrhythmic contractile motion on hiPSC-CMs based on PSR analysis, as this drug does not 
significantly affect the regularity and the complexity of the system. 
 
6.5.5  Isoproterenol 
Lastly, isoproterenol is a beta adrenoceptor agonist that treats bradycardia. This drug can accelerate 
the heart rate and potentially induce tachycardia. Application of isoproterenol significantly 
changed the embedding and fractal dimensions with increasing concentration of drug (Figure 39). 
In particular, the embedding dimension significantly decreased from the baseline control to a low 
dosage (50 nM) of isoproterenol. However, as the drug concentration increased further to 10 µM, 
the embedding dimension increased. This suggested that low concentrations of isoproterenol had 
the therapeutic effect of rescuing arrhythmic contractile motions to more regular and consistent 
motions. However, overdose of isoproterenol might cause the heart beating to lose its’ regular 
rhythm. The average fractal dimension increased with isoproterenol treatment, indicating that the 
contractile motion became more complex, partially due to the increase of beat rate. 
 
6.5.6  Conclusions of PSR drug response 
By analyzing the contractile motions of hiPSC-CMs exposed to these four drugs at different 
concentrations, we found that frequency analysis (beat rate) and amplitude analysis (MCV) could 
only prove the functionality of specific drug. For example, isoproterenol supposedly increased the 
beat rate and contraction velocity, while E4031 decreased both parameters. The risk level of drug-




induced arrhythmic motion was not well characterized solely relying on this analysis. However, 
by performing PSR analysis on these waveforms, we were able to characterize the system 
dynamics of the hiPSC-CMs contractile motion, and further compute their regularity and 
complexity as quantifications of drug risk level. For example, exposure of E4031 at low dosage 
would potentially induce arrhythmic contractile motion, while low dosages of isoproterenol could 
help regulate the heart rhythm and diminish the arrhythmia. 
 
6.6  Comparison of PSR responses to different assays of cardiac physiology 
6.6.1  Calcium flux assay 
Using GCaMP6f hiPSC-CMs, we validated the performance of the PSR algorithm on both optical 
flow motion analysis and calcium flux analysis, one of the standard assays of cardiac 
electrophysiology. GCaMP6f hiPSC line has been generated to visualize the calcium flux on the 
living hiPSC-CMs without any fluorescent markers24,151. PSR analysis is not only limited to the 
waveforms generated from the contractile motion tracking-based on the optical flow method. This 
analytical algorithm can be also used to analyze the waveforms of electrophysiological signals 
generated across a wide range of standard assays. By applying isoproterenol and propranolol to 
GCaMP6f hiPSC-CMs, we generated the corresponding waveforms from motion tracking analysis 
and the transient calcium flux (Figure 40a-c). We performed the PSR analysis on both contractile 
motion data and calcium flux data to determine the arrhythmic-like behaviors responding to 
different drug interference.  
 
6.6.2  PSR responses of motion tracking in comparison to calcium flux 




Based on the PSR analysis coupled with optical flow motion tracking, GCaMP6f hiPSC-CMs 
treated with isoproterenol showed an improvement in regularity (low embedding dimension and 
high regularity dimension) at a 10 nM drug concentration (Figure 40d). This trend was validated 
in the PSR analysis coupled with the calcium flux measurement, where we also observed low 
embedding dimensions and higher regularity upon exposure to the drug. This indicated that both 
approaches are sensitive to changes in the regularity of the system. We also observed increased 
fractal dimensions in response to 10 nM isoproterenol treatment from PSR coupled with motion 
tracking. However, this did not match with the calcium flux analysis, where we observed an overall 
fractal dimension decrease, indicating that physical contractions and electrophysiology represent 
different complexities in the cardiac physiology. By treating GCaMP6f hiPSC-CMs with 
propranolol at 10 µM (Figure 40e), we observed a significant increase in the embedding 
dimensions from the PSR algorithm coupled with both motion tracking and calcium flux. We also 
found a significant increase of fractal dimensions with the 10 µM propranolol addition from the 
PSR analysis of both assays. Thus, both assays coupled with PSR showed that treatment of 
propranolol reduced the regularity and subsequently enhanced the complexity of the cardiac 
physiology. These results indicated that electrophysiological assays coupled with PSR analysis not 
only validated our optical flow method, but also served as complimentary assessment for future 
multiplexed drug-induced arrhythmia analysis. 
 
We have determined that PSR analysis can be applied to two different approaches (contractile 
motion tracking and calcium flux measurement) for in vitro assessments of hiPSC-CM arrhythmic 
potential. To further compare the sensitivities of each assay to the drug interference when coupled 
with PSR algorithm, we performed statistical analyses (t-tests) on the PSR outputs (embedding 




and fractal dimensions) for the drug-treated hiPSC-CMs relative to baseline controls. We then 
cross-examined the p-values of the PSR data generated from motion tracking with those generated 
from calcium flux measurement. For GCaMPf6 hiPSC-CMs treated with isoproterenol, the p-
values computed from the embedding dimensions was less for motion tracking, compared to the 
calcium flux (p<0.0001 vs. p=0.0003). This was also consistent with the embedding dimensions 
calculated from propranolol treatment, where the p-values were p<0.0001 and p=0.0276 for 
motion tracking and calcium flux, respectively. For isoproterenol treated hiPSC-CMs, the p-value 
of the fractal dimensions was found to be larger for motion tracking (p=0.01) compared to the 
calcium flux (p<0.0001). From the propranolol treatment, the p-values of fractal dimensions 
between the motion tracking and calcium flux were comparable (p<0.0001). 
 
The smaller p-values calculated from the embedding dimensions coupled with motion tracking, a 
consistent trend between both drugs, indicated that the PSR regularity quantification is more 
sensitive to the physical contraction recorded using the motion tracking approach. P-values from 
analysis of the fractal dimension were found to be comparable between the motion tracking and 
the calcium flux assays of propranolol treatment. This suggests that the quantification of system 
complexity is equally sensitive to both assays, However, this was not consistent with isoproterenol 
treatment, where complexity computation was found to be more sensitive to the calcium flux (as 
indicated by the smaller p-value). This inconsistency was attributed to our previous observation, 
where the electrophysiology and the physical contraction represented different system 
complexities. 
 
6.7  Nonlinear characterization of contractile complexities  




6.7.1  Complexities represented by capacity and correlation dimensions 
The capacity and correlation dimensions are additional measures of complexity that complement 
the previously described fractal dimension. In order to determine the complexity of cardiac 
contractile dynamics, we performed PSR of the contractile motion waveforms recorded from 
hiPSC-CMs. To analyze the fractal properties of reconstructed phase space, we can compute 
capacity and correlation dimensions based on different methods (Figure 41a). After hiPSC-CM 
purification, we recorded the beating videos of hiPSC-CM clusters (Figure 41b), and compared 
the difference in both linear and nonlinear parameters between two independent tissue cluster 
samples (Cluster A vs. Cluster B). Motion waveforms corresponding to Cluster A and Cluster B 
were visibly comparable based on visual inspection (Figure 41c), which was corroborated with 
similar motion results (Table 4), including comparable beat rates (33.17 vs. 33.99 beats per 
minute), contraction velocities (24.65 vs. 22.46 µm/s), and relaxation velocities (18.69 vs.19.97 
µm/s). Based on these two motion waveforms, the peak-to-peak (PP) interval was also computed 
as a traditional linear assessment. Similarly, the average PP interval remained relatively consistent 
between both samples (1.81 vs. 1.77 seconds). Therefore, from motion tracking analysis, we 
concluded that these two samples exhibited similar contractile features based on linear time series 
analysis. 
 
Nonlinear PSR analysis was then applied to extend the characterization of these two contraction 
motion waveforms (Figure 41d, e). The raw data acquired from motion tracking analysis was 
processed using custom algorithms, from which we were able to calculate the capacity and 
correlation dimensions based on time lag (τ) and embedding dimension (m), respectively. The 
mean capacity dimension (Dcapacity) was also similar between two samples (1.354 vs. 1.350) (Figure 




41d), inferring that the geometrical capacity of phase space between two clusters was comparable. 
We also calculated and plotted the correlation dimension (Dcorrelation) with respect to embedding 
dimension, which is a measure of the dynamic distribution of points in the phase space (Figure 
41e). In contrast, Cluster B exhibited a greater steady correlation dimension (1.193 vs. 1.354). 
Therefore, the correlation dimension was able to detect the contrasts in system dynamics of the 
nonlinear plots between two samples exhibiting similar contractile behaviors. Computation of the 
correlation dimension provided quantification of additional aspect of the system dynamics, which 
were not visibly apparent in the motion waveforms as well as not reflected in the capacity 
dimension. 
 
6.7.2  Drug response 
To investigate the capability of our new analytical approach to evaluate the responsiveness of 
hiPSC-CMs to drug interference, hiPSC-CMs were exposed to three drug compounds (alfuzosin, 
flecainide and isoproterenol) known to modulate heart contractile behaviors. (Figure 42 and Figure 
43). For this study, we recorded the beating videos for both untreated baseline controls and drug-
treated hiPSC-CMs over short- and long-term drug exposure. For short-term dose-response 
assessment, hiPSC-CMs were treated with incremental doses of specific drugs and subsequently 
recorded as beating videos following each dosage. The videos were then analyzed with motion 
tracking to generate the corresponding waveforms (Figure 42a-c) and followed with nonlinear 
dimensional analysis. Alfuzosin is an alpha-adrenergic blocker prescribed to treat benign prostatic 
hyperplasia152. However, alfuzosin use has also shown adverse effects on prolongation of QT 
interval by delaying cardiac repolarization152. Treatment with alfuzosin significantly increased the 
beat rate of hiPSC-CMs but with negligible change in average contraction velocities (Figure 42d). 




Nonlinear analysis showed insignificant changes in capacity dimension with increasing dose. 
Alternatively, the drug treatment at both the 1 nM and 100 nM concentrations resulted in an 
observable decrease of the correlation dimension relative to the baseline control (Figure 43a). 
Next, hiPSC-CMs were treated with flecainide, which is a sodium ion channel blocker and is 
prescribed to restore normal heart rhythm from arrhythmias153. In contrast to alfuzosin, the 
introduction of flecainide caused a decrease in the beat rate, with slight, but insignificant increases 
in contraction velocities (Figure 42e). This corresponded to insignificant variations in capacity 
dimension and correlation dimension with each incremental dose (Figure 43b). Lastly, we treated 
the hiPSC-CMs with isoproterenol, which is a potent β adrenergic agonist that is used clinically to 
treat bradycardia. hiPSC-CMs treated with isoproterenol had significantly greater beat rate and 
contraction velocities (Figure 42f), as well as higher capacity and correlation dimensions (Figure 
43c).   
 
For the long-term drug exposure study, hiPSC-CMs were treated continuously with a constant dose 
(10 nM) of isoproterenol for 7 consecutive days, wherein the drug supplemented media was 
changed every two days and videos were recorded daily. Throughout the entire treatment period, 
the average contraction velocities of the tissues remained relatively consistent (Figure 42g, h). 
Regarding contraction frequency, a significant increase in beat rate was found only after the first 
hour of treatment. Subsequent days after, the contractile physiology returned to the baseline level, 
indicating desensitization of the hiPSC-CMs to the drug. The reduced sensitivity can be attributed 
to the fact that hiPSC-CMs are still physiologically immature with limited responsiveness to β 
adrenergic stimulation30,154. Regardless of the drug-induced changes to contractile physiology, the 
capacity dimension remained consistent with insignificant fluctuations, after the initial hour and 




over the 7-day period. In contrast, the correlation dimension exhibited significant variation only 
towards the last two days of treatment (Figure 43d).  
 
6.8  Conclusions and discussion 
A combination of optical flow-based motion tracking and PSR analysis was used to characterize 
and quantify the arrhythmic behavior of cardiac contractile motion. In this chapter, we 
reconstructed 1D time series of contractile motion waveforms obtained from optical flow analysis 
of hiPSC-CMs into a multi-dimensional phase space. Using nonlinear phase space reconstruction, 
we distinguished the different biological dynamics based on the embedding, regularity and fractal 
dimensions. These analyses were supplemented to traditional linear approaches to characterize 
contractile dynamics exhibited by hiPSC-CMs. Based on PSR analysis, we evaluated the drug-
induced arrhythmic contractile motion from hiPSC-CMs and concluded that the regularity and 
complexity of cardiac contractile motion changes in response to the drugs. 
 
The development of signal processing techniques in biomedical research remains a priority in order 
to diagnose and treat patients sooner. Because of its’ increasing recognition in clinical settings, we 
have extended phase space reconstruction signal analysis to in vitro cardiac model systems for 
characterizing the cardiac signals obtained from hiPSC-CMs. Implementation of optical-flow 
based motion tracking to hiPSC-CMs has allowed us to quantify the variations in contractile 
physiology, providing a linear time domain assessment of beat rate and contraction velocity. The 
essential effort of this work is to reconstruct these time series of experimental data into a multi-
dimensional phase space for nonlinear analysis on the contractile dynamics of hiPSC-CMs, 
providing a quantitative measure of in vitro system complexities. We envision that this integrated 




approach can potentially be useful for health monitoring and diagnostics, such as assessment of 
heart rate variabilities and for early predictions of disease onset. In addition, the application of this 
analytical toolbox in pharmacological cardiotoxicity is essential to better understand drug effects 











Figure 33. Process workflow of hiPSC-CM contractile motion characterization. The 
contractile motion of hiPSC-CMs was recorded as beating videos, which were analyzed using 
motion tracking software to generate motion vectors and contractile motion waveforms. This data 
was then analyzed using PSR to compute the dimensional parameters. The embedding dimension 
characterizes the regularity of the contractile motions, which reflects the changes in beat rhythm 
and overall gross motion. The fractal dimension characterizes the complexity, which reflects the 
secondary aberrations present within each beat cycle128.   
  





Figure 34. Reconstruction of cardiac motion waveforms into phase space. The phase spaces 
of a regular (a) and a complex (c) cardiac contractile motions are plotted along with their 
corresponding motion waveforms (b, d). The embedding dimensions from a single motion 
waveform were computed from PSR to compare the differences in regularity between two 
contractile motions (e). The regularity dimensions derived the embedding dimensions were plotted 
with respect to τ (f). The average fractal dimension across all τ was computed from PSR (g) and 
then plotted with respect to τ (h)128.  





Figure 35. PSR analysis of secondary system aberrations. A motion waveform was supplied 
with random noise ranging from 2.5%-50% (a), and corresponding phase space was reconstructed 
to compute the dimensional parameters respectively for different degrees of noise. No significant 
difference was found based on embedding and regularity dimensions among the contractile 
motions with different noise level (b, c), but fractal dimensions exhibited significant increase with 
the increase of the noise level (d, e)128.    





Figure 36. PSR analysis of propranolol treated hiPSC-CMs. The application of propranolol to 
hiPSC-CMs increased the average embedding dimension with the increase of drug concentrations, 
which correlated to a reduction in regularity dimension. No significant difference was found for 
fractal dimension between baseline control and drug exposure128.  





Figure 37. PSR analysis of E4031 treated hiPSC-CMs. E4031 induced significant increases in 
the embedding and regularity dimensions between controls and drug exposure. High dosage of 
E4031 (100 nM) induced a significant increase of fractal dimension on the hiPSC-CMs in 
comparison to the control and low dosage128.  





Figure 38. PSR analysis of metoprolol treated hiPSC-CMs. PSR analysis showed that treatment 
of hiPSC-CM with metoprolol has no significant influence on the embedding, regularity and fractal 
dimensions128.   





Figure 39. PSR analysis of isoproterenol treated hiPSC-CMs. Low dosage of isoproterenol (50 
nM) decreased the embedding dimension, which corresponded to a rise in the regularity of the 
system. In contrast, high dosage of isoproterenol (10 µM) increased the embedding and fractal 
dimensions, indicating the contractile motions of hiPSC-CMs gained aberrations but lost 
regularity128. 
  





Figure 40. Drug-induced arrhythmia comparison of motion tracking versus calcium flux. 
Brightfield and fluorescence videos of drug-treated GCaMP6f hiPSC-CMs were recorded for (a) 
motion tracking analysis and (b) calcium flux analysis. (c) Waveforms generated from each assay 
were subjected to PSR analysis. PSR analysis of both methods illustrated the sensitivities to drug 
interference by quantifying changes in the embedding and fractal dimensions as a result of (d) 
isoproterenol and (e) propranolol induced-arrhythmias128. All scale bars are 100 μm. 
  









Figure 41. Nonlinear reconstruction of time series contractile motion signals.(a) Contraction 
motion waveforms were analyzed using phase space reconstruction to determine the fractal 
properties of the signals, including two parameter capacity dimension and correlation dimension, 
which characterize the geometric space and distribution dynamics of the signals. (b) Two hiPSC-
CM clusters (Cluster A and Cluster B) exhibiting comparable contractile physiology, (c) which 
were compared in time domain and respective nonlinear phase spaces. (d) The capacity dimension 
with respect to time lag (τ) was comparable between the two clusters, (e) but the correlation 
dimension with respect to embedding dimension (m) showed different trends129. Scale bars = 100 
μm. 
  




Table 4. Comparison of linear and nonlinear parameters of Cluster A and Cluster B129. 
  
  Cluster A Cluster B 
Beat Rate (BPM) 33.17 ± 0.349 33.99 ± 0.227 
Peak-Peak Interval (s) 1.81 ± 0.016 1.765 ± 0.012 
Contraction Velocity (µm/sec) 16.02 ± 0.187 14.599 ± 0.143 
Relaxation Velocity (µm/sec) 12.15 ± 0.075 12.98 ± 0.142 
Mean Capacity Dimension 1.354  1.350  
Steady Correlation Dimension 1.193 1.354 





Figure 42. Contractile velocities of hiPSC-CMs exposed to drug compounds. Short term 
changes to contraction motion waveform and average contraction velocities were observed in 
hiPSC-CMs treated (a, d) alfuzosin, (b, e) flecainide and (c, f) isoproterenol. (g, h) Long-term 
treatment of hiPSC-CMs with isoproterenol showed negligible changes in both contraction and 
relaxation velocities over a 7-day period129.   





Figure 43. Fractal changes on hiPSC-CM drug response. hiPSC-CMs was treated with 3 drugs, 
including (a) alfuzosin, (b) flecainide and (c) isoproterenol over a short period with incremental 
doses. The beat rate, capacity dimension and correlation dimension were compared respectively 
in response to the drug dosages. (d) A long-term drug study was also conducted by supplying a 
constant dose of isoproterenol over the course of 7 days129.   




7. Chapter 7: Summary  
 
Conclusions 
This dissertation discusses engineering and development of novel tools and methodology to model 
heart development and characterize cardiac physiology for advanced diagnostic capabilities, 
especially for drug-induced cardiotoxicity. This dissertation primarily focused on engineering 
cardiac organoids using micropatterning to govern the organoid cell assembly and tissue 
differentiation. In Chapter 3, we exploited how pattern geometry, such as shape and size, 
influences 3D cardiac tissue formation and cardiac contractile functions to optimize the organoid 
engineering. In Chapter 4, we applied the cardiac organoid platform as an embryotoxicity 
screening assay to evaluate the potential of this platform as an alternative in vitro screening method 
for developmental toxicity. Chapter 5 explores the cardiac organoid cellular composition using 
high resolution single-cell genomics and bioinformatics analysis. Lastly, Chapter 6 discusses a 
novel computational tool based on nonlinear phase space reconstruction to quantitatively 
characterize cardiac contraction functions of engineered cardiac tissue, especially for drug-related 
cardiotoxicity. This work illustrates the engineering, application, and characterization of cardiac 
organoids based on micropatterning technology as well as novel methods for cardiotoxicity drug 
screening. We envision that this work will provide opportunities to advance cardiovascular 
research through novel use of tissue engineering and computational approaches.  
 
7.1 Geometric confinement on cardiac organoid development 
Chapter 3 exploited how pattern geometry influences cardiac organoid tissue differentiation, 
structure, and contractile function. Pattern shape significantly influences the ability of the 




patterned hiPSCs to differentiate into robust cardiac tissue. Circular geometry produced cardiac 
organoids with the largest cardiac tissues based on 3D architecture and cardiac tissue area fraction, 
which was proportional to the contraction velocity. When organoid differentiation was performed 
in polygonal triangles and squares, the contracting cardiac tissues became smaller with a larger 
fraction of smooth muscle-like stromal cells relative to the circular organoids. This suggested that 
the biophysical stresses of the sharp corners of polygonal geometries promotes the differentiation 
into stromal cells. In addition, pattern size proved to be a limiting factor in the 3D morphogenesis 
of the cardiac organoids, where parameters of 3D architecture peaked at mid-sized (600 μm) 
patterns. This work not only illustrates the versatility in organoid engineering via micropatterning, 
but also how researchers can use micropatterning to tailor and fine-tune stem cell organoids using 
biophysical confinement.  
 
This work can be expanded through additional comprehensive functional screenings.  For instance, 
screening of transient calcium is a common tool to study cardiac contraction, as intracellular 
calcium flux is directly correlated to a muscle contraction. Using GCaMP6f hiPSC lines, we can 
generate cardiac organoids for an integrated analysis of contraction motion with transient calcium 
for a more comprehensive view of relationships between organoid structure-function and organoid 
engineering parameters. 
 
7.2 Cardiac organoids as an embryotoxicity screening platform 
Chapter 4 assessed the potential applicability of cardiac organoids as an embryotoxicity platform. 
Since the organoids are generated from the self-assembly of differentiating hiPSCs, we 
hypothesized that this process could recapitulate in vivo heart development. This would potentially 




alleviate current limitations in fetal drug toxicity testing and provide safer alternative in medication 
prescribing decisions for pregnant women. Upon exposure to a variety of drugs ranging in safety 
classification, we found that the cardiac organoid formation was sensitive to continuous drug 
exposure, especially for well-known toxic drugs, such as thalidomide (category X). Contrastingly, 
the organoids were not affected by well-known safe drugs, such as doxylamine succinate (category 
A). The organoids also showed varying toxicity for drugs with safety classifications ranging in 
between doxylamine succinate and thalidomide, with increasing toxicity as we tested drugs along 
the pregnancy drug classification spectrum. In addition, toxicity was manifested as impairments 
that were unique to each drug. These studies showed that this cardiac organoid platform not only 
is sensitive to drug exposure, but it can also classify developmental toxicity to identify cellular 
developmental processes that the drug is targeting.  
 
Through this work, we have established that cardiac organoid development is sensitive to drug 
exposure, which is manifested as structural and/or functional impairment. As a potential model for 
human heart development, this work can be expanded to study the chamber development over 
time. By integrating time-lapse microscopy, we can identify events in organoid development that 
are targeted by drug compounds and correlate these events with human organogenesis. 
Furthermore, integration of genomic characterization through PCR and RNA sequencing can 
reveal specific drug pathway targets.  
 
7.3 Single cell characterization of cardiac organoids using next generation sequencing 
technologies 




Chapter 5 explored the cardiac organoid composition using single cell genomics. Based on the 
bioinformatics analysis, cardiac organoids were interestingly composed of approximately 10 cell 
types along three trajectory lineages: cardiac, stromal, and endodermal. We then evaluated the 
influence of geometric confinement on organoid lineage specifications by generating organoids in 
small (200 µm), mid-size (600 µm), and large (1000 µm) circle patterns.  Cardiac organoids 
generated from very small patterns (200 µm) were primarily composed of less definitive and 
premature cells indicative of progenitor cell types. Cardiac and smooth muscle cell specification 
was optimal in mid-sized 600 µm organoids and that larger sizes (1000 µm) drives the organoid 
specification to endodermal cell lineages.  This study not only demonstrated the importance of size 
restraint on organoid engineering but also how engineering parameters heavily influence cell fate 
specification. Understanding the cellular diversity that make up the cardiac organoids will advance 
organoid research by providing a more integrated and comprehensive evaluation of organoid 
function and structure based on individual cell contributions as well as overall cell composition. 
In addition, this data can provide insight on biological regulatory mechanisms involved in human 
development via biophysical cues, allowing us to better understand the role potential biophysical 
factors in vivo on organ development.  
 
In order to correlate organoid genomics with organ development, future work will require genomic 
and bioinformatics analysis of cardiac organoids over time. Therefore, future work includes 
bioinformatics processing of organoids at various timepoints throughout differentiation. Our 
differentiation targets will include timepoints before and after small molecule introductions. This 
will allow us to understand which developmental pathways are being targeted by the small 
molecules and correlate these developmental events with genomic datasets of target organs 




provided on public databases. For instance, we aim to compare our organoid development with in 
vivo mouse heart development as well as liver development based on the trajectories that were 
revealed in Chapter 5.  
 
7.4 Quantitative characterization of drug-induced cardiac arrhythmias using nonlinear 
computational tools  
Chapter 6 discussed the development and application of a signal processing workflow to 
characterize contraction physiology of hiPSC-CMs, particularly for drug screening applications. 
Phase space reconstruction and nonlinear analytical toolboxes were used to analyze contraction 
motion and distinguish biological signal dynamics based on various nonlinear variables. hiPSC-
CMs treated with various drugs influencing heart rhythm showed changes in signal regularity and 
complexity in response to these drugs, demonstrating the application of the analytical workflow in 
drug screening for cardiotoxicity. The development of signal processing techniques in biomedical 
research remains a priority in order to diagnose and treat patients sooner and more precisely. The 
essential effort of this work is to reconstruct these time series of experimental data into a multi-
dimensional phase space for nonlinear analysis on the contractile dynamics of hiPSC-CMs, 
providing a quantitative measure of in vitro system complexities. We envision that this integrated 
approach can potentially be useful for health monitoring and diagnostics, such as assessment of 
heart rate variabilities and for early predictions of disease onset. 
 
We envision that this work can have wide applications, as the algorithms are versatile and can be 
applied to any type of cardiac signal. The work in Chapter 6 demonstrated the applicability to 
studying the drug response of cardiac contraction signals. Therefore, this can be implemented to 




work that was discussed in Chapter 3 and Chapter 4, which discuss biophysical and drug-related 
influences on cardiac contractile functions. In addition, our lab is currently exploring machine 
learning methods to provide a comprehensive and systematic view of structure-function 
relationships of cardiac organoids. Using machine learning to integrate the nonlinear metrics with 
standard assays of cardiac organoid function will allow us to better understand cardiac physiology 
with much larger scale datasets, which will facilitate better prediction of drug-related 
cardiotoxicity.  
  






Appendix A: Calculation of phase space reconstruction parameters 
A.1 Computation of the embedding, regularity, and fractal dimensions 
The principle of this approach is to transform the properties of a time series into topological 
properties of a geometrical object embedded in a space, in which all possible states of the system 
are represented and each state corresponds to a unique vector 155. Mathematically, the states of a m 
dimensional dynamic system can only be characterized by m independent quantities that represent 
the coordinates of the phase space. Unfortunately, this representation is not possible for 
experimental data, because it is a 1D time series. Starting on the conjecture that all groups of m 
values should give equivalent results, it is then possible to construct m-vectors that contain the 
same information as the original state vectors: this is the principle of the time lagged method 156, 
which simply takes m consecutive elements of the time series directly as coordinates in the phase 
space. The challenge is to find the appropriate number m, such that the properties of the initial time 
series are kept in the reconstructed space. A method consisting of building a m dimensional system 
from a 1D time series with a fixed delay to shift the original data (time lagged method) has been 
introduced by Takens156. 
 
Let be the system states with a normalized sample step T = 1, τ !ℕ∗, while 𝑖 = 1, 2, …𝑛 are the 
indices of the successive samples values of the cardiac contraction motion waveform s: 
 𝑉(𝜏,𝑚) = 	 [𝑆(𝑖), 𝑆(𝑖 + 𝜏), … 𝑆(𝑖 + (𝑚 − 1)𝜏)],                                 (1) 
where V is a matrix containing the phase space vectors: 

















𝑠(1) 𝑠(2) . . . 𝑠(𝑁 − (𝑚 − 1)𝜏)
𝑠(1 + 𝜏) 𝑠(2 + 𝜏) . . . 𝑠(𝑁 − (𝑚 − 2)𝜏)
. . . . . .
. . . . . .
. . . . . .











                (2) 
 
Next, Takens theorem156 gives conditions under which a nonlinear dynamical system can be 
reconstructed from a sequence of observation of its states. The state space vectors are obtained 
from the sample signal according to the embedding dimension m and the time delay τ. The 
embedding dimension m is computed for each time delay τ based on False Nearest Neighbor 
(FNN) method, and resulting phase space vectors obtained from (1) are:  
 
𝑉(1, 3) = @𝑆(𝑖), 𝑆(𝑖 + 1), 𝑆(𝑖 + 2)A,                                            (3) 
𝑉(3, 3) = @𝑆(𝑖), 𝑆(𝑖 + 3), 𝑆(𝑖 + 6)A,                  (4) 
𝑉(6, 3) = @𝑆(𝑖), 𝑆(𝑖 + 6), 𝑆(𝑖 + 12)A,                                         (5) 
𝑉(9, 2) = @𝑆(𝑖), 𝑆(𝑖 + 9)A,                                                           (6) 
 
The phase space reconstruction is influenced by the parameter time lag τ. If τ is too small, the 
trajectories of 𝑆(𝑖) and 𝑆(𝑖 + 𝜏) are close to one another, potentially making it indistinguishable 
and creating redundant coordinates. This implies that the trajectories of attractor projected on the 




two axes are not correlated, which makes the phase space reconstruction useless. For this reason, 
the basic criterion for choosing τ should be the largest value of τ resulting coordinates relatively 
independent. Without prior knowledge of the system, especially for experimental data, properly 
determining this parameter is not apparent. Therefore, in this study, for cardiac contraction motion 
waveforms, the time lag τ has been varied form τ = 1 - 50.  
 
To estimate the embedding dimension m, we used FNN method, where the best value of m 
corresponds to the minimum value of m for which the FNN is close to zero 157. From a geometrical 
point of view, the time series (experimental measurements) is the projection of a m dimensional 
system to a 1D space. Therefore, two points in a m dimensional space, even far from each other, 
could be very close (and even be superimposed) in the original 1D space. These points are called 
false neighbors. If m is not large enough, the state vectors on the trajectories could be very close 
with possibility of intersections between the trajectories of the attractor, which will result in a 
reconstructed space totally different from the original one. A higher value of m, theoretically, is 
possible by just creating a larger space that contains minimal space. However, this will cause 
redundant problems and inefficiency issue, as it requires significantly strong computation power. 
The main idea behind this method is to determine an appropriate value of m as follows: 
• We begin the reconstruction with vectors of delay 𝑆(𝑖) of dimension m small 
enough; 
• We determine the neighbors of each	𝑆DDD⃗ (𝑖)	by checking E𝑆(𝑗) − 𝑆(𝑖)E ≤ 𝜀, where 𝜀 
is a length appropriate to the problem and containing the number of these 
neighbors;  
• We increase m until the neighbor numbers stabilize. 




To quantify the regularity of the time series of cardiac contraction waveform, we introduce a new 
parameter called “Regularity Dimension” noted as 𝜌, which is defined as: 
𝜌 = $
%
                                                                            (7) 
 
To quantify the complexity of time series of cardiac contraction waveform, we computed the 
fractal dimension d using Boxcount method and Variation estimator. In the case of Boxcount 
method, it is supposed that the original time series graph is fully covered by a box. The box is 
divided into four sub-boxes, for example. The number of boxes needed to cover the entire time 
series is counted. Following the same rule, these sub-boxes are divided into smaller boxes. The 
different box sizes (𝛼) (also called scales) and the number N of validated boxes are recorder. The 





                       (8) 
The “Variation estimator” is based on the 2nd order Variogram of a stochastic process as 
described in 158,159. In this case, a fractal dimension is computed for each value of the time lag τ.  
 
A.2 Characterizing nonlinear complexity via Capacity and Correlation Dimensions 
The capacity dimension of contraction motion waveforms was calculated using the variogram 
method based on a “variation estimator”158. The variation estimator plots the variance γ (𝜏) of 
values given for the points separated by a certain distance 𝜏, given by 
    (1) 
where N is the number of neighboring data points within the time lag distance specified, Si+1:N is 
the value of the initial point, and S1:N-i  is the value of the neighboring point being compared in the 
γ (τ ) = 1
2(N −τ )











range of i bounded by the time lag distance 𝜏 and the length N of the contraction motion waveform 
S. Thus, for computing capacity dimension using variogram approach, first step is to compute the 
variance γ(𝜏) for different time lag 𝜏. This can be plotted as a curve, in which the variogram value 
increases with time lag to a maximum, and levels off at a time lag where the total variability of the 
data field is reached. Next, log(γ(𝜏)) vs. log(𝜏) is plotted, and regression method is used to calculate 
the slope P of the line. Finally, the capacity dimension is given by 
𝐷12321456 = 2 − 𝑃/2       (2) 
 
The correlation dimension (Dcorrelation) measures the geometrical complexity of an attractor160  
and has become a standard measure of the fractal properties of attractors that have been 
reconstructed in the state space. A larger value of the correlation dimension depicts a higher degree 
of complexity in the signal dynamics. If the dynamics is stochastic, D tends to infinity and the 
attractor is obtained when the signal is embedded in a phase space. From a cardiac contractile 
motion waveform (Sn; n = 1, …, N) with N samples, considering Takens theorem156, an m-
dimensional phase-space is constructed as follows: 
 
𝑥7DDD⃗ = U𝑆8 , 𝑆89$, 𝑆89:$, … , 𝑆89(%;<)$V      (3) 
𝑗 = 1,… ,𝑁 − (𝑚 − 1)𝜏 
 
The phase space reconstruction depends on two parameters: time lag τ and embedding dimension 
m. If τ is too small, the trajectories of Sj and Sj+τ are too close to be separated. In contrast, if τ is 
too large, the trajectories of attractor projected on the two axes are not correlated, which makes 
the reconstructed phase space useless. The goal is to find the smallest value of τ to ensure the 




independence of resulted coordinates in the phase space. Herein, the time lag τ is computed using 
the method of autocorrelation function (ACF)161, and it corresponds to the time required for the 
ACF to decrease to 1/e of its original value as follows: 
𝐶(𝜏) = 𝐶(0)𝑒;=$    (4)  
where C(0) is calculated without a time lag (τ = 0). τ can be defined when 𝐶(𝜏) = >(()
?
 (where k = 
1/τ), which corresponds to the time required for the ACF to decrease to 1/e of its original value.  
 
In terms of the embedding dimension m, a well-defined embedding dimension is essential to a 
phase space to describe all possible states of a dynamic system. Since the dimension of the phase 
space reconstructed from experimental data is not known in priori, embedding dimension m will 
be determined to ensure that reconstructed phase space is topologically identical to original data. 
From a geometrical point of view, the time series (experimental data) is the projection of a m-
dimensional system (reconstructed phase space) to a one-dimensional space. Therefore, two points 
in the m-dimensional space, even far from each other, could be very close in the original 1D space, 
which makes them false neighbors. In the reconstructed phase space, the distances between a point 
and its nearest neighbor will be measured. If two points are real nearest neighbors, the distance 
will not change with the increase of dimension. Herein, the embedding dimension m is estimated 
using the method of False Nearest Neighbors (FNN)162, where the optimal value of m corresponds 
to the minimum value of m for which the FNN is close to zero.  
 
In our work, the correlation dimension is determined using the Grassberger-Procaccia method163, 
based on the following approximation: the probability of having a couple of points in a box of size 




r is equal to the probability of having a couple of points with separation distance less than r when 
𝑟 → 0. The correlation dimension is defined by: 
  
𝐷1@AA?B254@C = limA→( \
,-.DE#(A)F
,-.(A)
]     (5) 
 





∑ 𝛩(𝑟−∥ 𝑥8 − 𝑥4 ∥))8G<,4I8     (6) 
 
where Θ(x) is the Heaviside step function. The summation counts the number of pairs (xi xj) for 
which the distance || xi, xj || is less than r. For each reconstructed phase space trajectory, the 
distances between all points in the trajectory are calculated. The logarithm of the smallest distance 
(represented by rmin) and the logarithm of the largest distance (represented by rmax) are then 
computed. A series of bins is created to record the correlation sum, Cm(r), which is the normalized 
number of couples of points with a separation distance less than a specified distance r. The process 
of depositing counts of data into bins is analogous to recording counts of the occurrence of events 
within data in a frequency histogram. In this study, an arbitrary number of 32 bins is used and the 
width of each bin is set to A$%&;A$'(
J:
 .Thus, from first to last, the separation distances 𝑟C 	= 𝑟%4C +
C(A$%&;A$'()
J:
 , where n = 1 to 32 are considered. In practice, the correlation dimension is obtained 
from the slope of log (Cm(r)) versus log (r). Several Cm(r) are computed for increasing values of 
the embedding dimension m, and the slopes are determined from a scaling region of the log-log 
plot. When m increases, Dcorrelation reaches to a saturation value corresponding to a steady 




correlation dimension164,165. From the distribution of the correlation dimension values, the 
averaged value of the correlation dimension of this set is computed. Based on the curvature of 
Dcorrelation values, the steady correlation dimension corresponding to the curve plateau was 
computed for each set of Dcorrelation. 
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